[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1169
1. Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD: Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol; 2008 Jun;109(3):323-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Response Evaluation Criteria in Solid Tumors (RECIST) response was assessed by computed tomography (CT).

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):355-7 [10955863.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2755-63 [17602081.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):140-4 [11748990.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):48-51 [12694653.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3402-8 [12885837.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):644-7 [14766260.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):363-8 [15140550.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):626-32 [6344983.001]
  • [Cites] Am J Clin Oncol. 1986 Feb;9(1):18-20 [3953489.001]
  • [Cites] Cancer Treat Rep. 1987 Dec;71(12):1303-4 [3690545.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):32-4 [2154921.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6823-6 [2208147.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):491-8 [1999720.001]
  • [Cites] Invest New Drugs. 1991 May;9(2):207-8 [1874603.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1962-6 [1941054.001]
  • [Cites] Am J Obstet Gynecol. 1992 Feb;166(2):556-9 [1536229.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):202-5 [1592288.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] Gynecol Oncol. 1996 Apr;61(1):27-30 [8626112.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):226-9 [8751554.001]
  • [Cites] Am J Clin Oncol. 1998 Apr;21(2):145-6 [9537200.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):267-71 [9740703.001]
  • [Cites] Stat Med. 1998 Oct 30;17(20):2301-12 [9819829.001]
  • [Cites] Gynecol Oncol. 1999 Sep;74(3):346-9 [10479491.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5484-92 [16110008.001]
  • [Cites] Cancer. 2006 May 1;106(9):2051-7 [16568459.001]
  • [Cites] Tumori. 2006 Nov-Dec;92(6):542-4 [17260498.001]
  • [Cites] J Thorac Oncol. 2006 Jun;1(5):447-53 [17409898.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):508-16 [17306350.001]
  • [Cites] Invest New Drugs. 2007 Jun;25(3):279-81 [17221305.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1248-55 [11230465.001]
  • (PMID = 18394689.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] None / None / / U10 CA027469-22; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / CA27469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / U10 CA027469-22
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ NIHMS55728; NLM/ PMC2692926
  •  go-up   go-down


2. Gharbi O, Ben Hadj Hassen S, Kaabia N, Limam S, Hadj Amor M, Ben Fatma L, Landolsi A, Hochlef M, Letaief A, Boukadida J, Ben Ahmed S: [Chemotherapy-induced febrile neutropenia: about 200 episodes. Clinical, microbiological and therapeutic characteristics]. Pathol Biol (Paris); 2008 May;56(3):154-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determinate the clinical, therapeutic and evolutive characteristics in patients treated essentially for solid tumors.
  • It has been noticed that 26.3% of patients have diabetes, the dominate neoplasm was solid tumors in 79.7%, 65% of patients have received preventive colony-stimulating factors, 83% have received preventive buccal disinfection with antifungic.
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / adverse effects. Bacterial Infections / complications. Bacterial Infections / drug therapy. Child. Child, Preschool. Fever / etiology. Humans. Infant. Middle Aged. Neoplasms / complications. Neoplasms / drug therapy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18178025.001).
  • [ISSN] 0369-8114
  • [Journal-full-title] Pathologie-biologie
  • [ISO-abbreviation] Pathol. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


3. Dapprich DC, Weenig RH, Rohlinger AL, Weaver AL, Quan KK, Keeling JH, Walsh JS, Otley CC, Christenson LJ: Outcomes of melanoma in recipients of solid organ transplant. J Am Acad Dermatol; 2008 Sep;59(3):405-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of melanoma in recipients of solid organ transplant.
  • BACKGROUND: There is concern that the immunologic tumor malignant melanoma (MM) may have worse outcomes in immunosuppressed hosts than in the general population.
  • OBJECTIVE: We sought to describe outcomes of MM in immunosuppressed solid organ transplant recipients and compare them with the general population.
  • METHODS: We conducted a retrospective review of medical charts and pathology slides of cases of MM and solid organ transplantation between 1978 and 2007, with comparison of outcomes.
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies. Time Factors. United States

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556089.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Stark AM, Tscheslog H, Buhl R, Held-Feindt J, Mehdorn HM: Surgical treatment for brain metastases: prognostic factors and survival in 177 patients. Neurosurg Rev; 2005 Apr;28(2):115-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients underwent craniotomy for the resection of solid tumor brain metastases between 1994 and 2001 in our department.
  • [MeSH-major] Brain Neoplasms / surgery. Craniotomy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Glasgow Outcome Scale. Humans. Male. Middle Aged. Reoperation. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CNS Drugs. 2002;16(5):325-38 [11994022.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):605-16 [7674008.001]
  • [Cites] J Neurol. 1998 Mar;245(3):127-31 [9553840.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):265-73 [11263507.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):537-47 [12057099.001]
  • [Cites] Med Oncol. 2000 Nov;17(4):279-86 [11114706.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1625-9 [3171628.001]
  • [Cites] Onkologie. 2002 Oct;25(5):480-1 [12415204.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):765-73 [8625178.001]
  • [Cites] Radiologe. 1995 Nov;35(11):816-21 [8657883.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1677-85 [10223560.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1746-54 [9351543.001]
  • [Cites] J Neurol. 2002 Oct;249(10):1357-69 [12382150.001]
  • [Cites] Curr Probl Cancer. 1999 Mar-Apr;23(2):59-98 [10333375.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):999-1007 [14983496.001]
  • [Cites] Curr Treat Options Oncol. 2000 Dec;1(5):447-58 [12057152.001]
  • [Cites] Onkologie. 2001 Jun;24(3):246-55 [11455217.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):600-4 [7674007.001]
  • [Cites] Gan To Kagaku Ryoho. 1990 Apr;17(4 Pt 2):761-7 [2344191.001]
  • [Cites] Urology. 1996 Feb;47(2):187-93 [8607231.001]
  • [Cites] Neurosurgery. 1979 Nov;5(5):617-31 [93255.001]
  • [Cites] Cancer. 2002 May 15;94(10):2698-705 [12173339.001]
  • [Cites] Lancet. 1975 Mar 1;1(7905):480-4 [46957.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):447-57 [8823774.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Aug;128(8):417-25 [12200598.001]
  • (PMID = 15609059.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Tokuda Y, Chinen K, Obara H, Joishy SK: Intervals between symptom onset and clinical presentation in cancer patients. Intern Med; 2009;48(11):899-905
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among patients with solid tumors, those with metastasis are likely to present to a physician more promptly.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / therapy. Registries. Retrospective Studies. Time Factors. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483358.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG: Undifferentiated carcinoma of the endometrium. Am J Surg Pathol; 2005 Oct;29(10):1316-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Undifferentiated carcinoma arising in the endometrium is considered a rare neoplasm with only a few studies published thus far.
  • This limited number of studies is most likely a reflection of the underrecognition of this tumor because of a lack of diagnostic criteria to separate it from endometrial endometrioid adenocarcinoma, FIGO grade 3.
  • Undifferentiated carcinoma was characterized by a proliferation of medium-sized, monotonous, epithelial cells growing in solid sheets with no specific pattern.
  • The solid component was different from the one seen in the undifferentiated carcinomas because well demarcated trabeculae, cords, or groups of cells were identified in all cases.
  • The tumor cells in the solid areas resembled the cells in the glandular component of the tumor.
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160474.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Shadad FN, Ramanathan RK: 17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I study. Clin Lymphoma Myeloma; 2006 May;6(6):500-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 17-dimethylaminoethylamino-17-demethoxygeldanamycin in patients with advanced-stage solid tumors and lymphoma: a phase I study.
  • [MeSH-minor] Adult. Bone Marrow / pathology. Humans. Neoplasm Staging. Patient Selection

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16796784.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Lactams, Macrocyclic; 001L2FE0M3 / 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
  •  go-up   go-down


8. Monteil J, Mahmoudi N, Leobon S, Roudaut PY, El Badaoui A, Verbeke S, Venat-Bouvet L, Martin J, Le Brun-Ly V, Lavau-Denes S, Maubon A, Bouillet P, Pouquet M, Vandroux JC, Tubiana-Mathieu N: Chemotherapy response evaluation in metastatic colorectal cancer with FDG PET/CT and CT scans. Anticancer Res; 2009 Jul;29(7):2563-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Response Evaluation Criteria In Solid Tumors (RECIST) and European Organisazion for Research and Treatment of Cancer (EORTC) criteria were used to evaluate CT and PET respectively.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Neoplasm Metastasis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596929.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


9. Temel JS, Greer JA, Admane S, Solis J, Cashavelly BJ, Doherty S, Heist R, Pirl WF: Code status documentation in the outpatient electronic medical records of patients with metastatic cancer. J Gen Intern Med; 2010 Feb;25(2):150-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Retrospective review of 2,498 patients with metastatic solid tumors at an academic cancer center.
  • PARTICIPANTS: The sample consisted of adult patients with metastatic prostate, breast, ovarian, bladder kidney, colorectal, non-colorectal gastrointestinal (GI), and lung cancers.
  • [MeSH-minor] Adult. Aged. Female. Humans. Longitudinal Studies. Male. Middle Aged. Neoplasm Metastasis / therapy. Resuscitation Orders. Retrospective Studies

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Geriatr Soc. 2000 May;48(5 Suppl):S194-8 [10809475.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4131-7 [18757326.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):307-14 [14722040.001]
  • [Cites] Hastings Cent Rep. 2004 Mar-Apr;34(2):30-42 [15156835.001]
  • [Cites] Arch Intern Med. 2004 Jul 26;164(14):1501-6 [15277279.001]
  • [Cites] J Am Med Inform Assoc. 2004 Sep-Oct;11(5):403-9 [15187069.001]
  • [Cites] N Engl J Med. 1991 Mar 28;324(13):889-95 [2000111.001]
  • [Cites] JAMA. 1995 Nov 22-29;274(20):1591-8 [7474243.001]
  • [Cites] J Gen Intern Med. 1996 Nov;11(11):651-6 [9120650.001]
  • [Cites] J Am Geriatr Soc. 1997 Apr;45(4):508-12 [9100722.001]
  • [Cites] J Crit Care. 1997 Dec;12(4):155-60 [9459110.001]
  • [Cites] Arch Intern Med. 1998 May 25;158(10):1090-5 [9605780.001]
  • [Cites] JAMA. 1998 Jun 3;279(21):1709-14 [9624023.001]
  • [Cites] J Gen Intern Med. 1999 Jan;14(1):15-20 [9893086.001]
  • [Cites] Ann Intern Med. 1999 Jan 19;130(2):116-25 [10068357.001]
  • [Cites] Resuscitation. 2006 Nov;71(2):152-60 [16987581.001]
  • [Cites] Am J Hosp Palliat Care. 2007 Jun-Jul;24(3):224-9 [17601847.001]
  • [Cites] Ann Intern Med. 2007 Jul 3;147(1):51-7 [17606961.001]
  • [Cites] J Hosp Med. 2007 Nov;2(6):366-71 [18080337.001]
  • [Cites] Am J Med. 2001 Aug 15;111(3):218-23 [11530033.001]
  • (PMID = 19894078.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2837502
  •  go-up   go-down


10. Holmäng S, Lele SM, Johansson SL: Squamous cell carcinoma of the renal pelvis and ureter: incidence, symptoms, treatment and outcome. J Urol; 2007 Jul;178(1):51-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular invasion, microscopic solid tumor pattern and large tumor size had negative prognostic significance in multivariate analyses.
  • Histopathological tumor type (squamous cell carcinoma or urothelial carcinoma) had no prognostic significance.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome. Urothelium / pathology


11. Chen RX, Xia YH, Cui JF, Xue TC, Ye SL: Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection. J Gastroenterol Hepatol; 2010 Aug;25(8):1435-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection.
  • BACKGROUND AND AIM: Osteopontin (OPN) has been linked to clinical outcomes in several solid tumors.
  • However, it has not been fully evaluated whether OPN could be used as a single marker for the prognosis of patients with hepatocellular carcinoma (HCC), particularly in patients of the tumor-node-metastasis (TNM) stage I.
  • [MeSH-minor] Adult. Aged. China. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Risk Assessment. Risk Factors. Time Factors. Tissue Array Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20659235.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / SPP1 protein, human; 106441-73-0 / Osteopontin
  •  go-up   go-down


12. Crispen PL, Boorjian SA, Lohse CM, Sebo TS, Cheville JC, Blute ML, Leibovich BC: Outcomes following partial nephrectomy by tumor size. J Urol; 2008 Nov;180(5):1912-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes following partial nephrectomy by tumor size.
  • PURPOSE: Pathological evaluation of renal tumors treated with ablative and observational therapy is often limited and renal tumor size may be the only prognostic index available.
  • We established long-term survival in patients following partial nephrectomy according to tumor size.
  • MATERIALS AND METHODS: A retrospective review of our nephrectomy registry was performed to identify patients who underwent partial nephrectomy for localized (NX/N0/cM0) solid renal tumors 7 cm or less at our institution between 1970 and 2004.
  • Overall, cancer specific, distant metastasis-free and local recurrence-free survival was estimated using the Kaplan-Meier method and stratified according to tumor size in all tumors treated and in patients with pathologically confirmed renal cell carcinoma.
  • RESULTS: We identified 798 patients who underwent partial nephrectomy for a 7 cm or less renal tumor.
  • Median patient age was 63.5 years and median tumor size was 3.0 cm.
  • Tumor size represents a valuable prognostic index in the absence of pathological evaluation of the entire tumor specimen.
  • These results may be used for comparison against outcomes following ablative and observational therapy, for which tumor size is the only prognostic index available.
  • [MeSH-major] Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Nephrectomy / methods. Tumor Burden
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Laparoscopy / adverse effects. Laparoscopy / methods. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / mortality. Probability. Prognosis. Proportional Hazards Models. Registries. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2009 Sep;182(3):1232; author reply 1232 [19625039.001]
  • (PMID = 18801543.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Polyzos A: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol; 2008 Feb;108(3-5):261-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
  • Its antitumor activity may result from both inhibition of angiogenesis and direct antiproliferative effects on certain tumor types.
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Female. Gastrointestinal Stromal Tumors / drug therapy. Humans. Lung Neoplasms / drug therapy. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Neuroendocrine Tumors / drug therapy. Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17945482.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Number-of-references] 29
  •  go-up   go-down


14. Wada-Hiraike O, Yamamoto N, Osuga Y, Yano T, Kozuma S, Taketani Y: Aberrant implantation and growth of uterine leiomyoma in the abdominal wall after laparoscopically assisted myomectomy. Fertil Steril; 2009 Nov;92(5):1747.e13-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENT(S): One 27-year-old woman with a newly developed solid mass in the abdominal wall near the minilaparotomic site of a previous laparoscopically assisted myomectomy.
  • [MeSH-minor] Abdominal Wall. Adult. Embryo Implantation / physiology. Female. Gynecologic Surgical Procedures / adverse effects. Humans. Neoplasm Recurrence, Local / complications. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / etiology


15. Costa SR, Cabral NM, Abhrão AT, Costa RB, Silva LM, Lupinacci RA: Giant cystic malignant pheochromocytoma invading right hepatic lobe: report on two cases. Sao Paulo Med J; 2008 Jul;126(4):229-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differing from the more frequent solid pheochromocytomas, which produce catecholamines and present adrenergic syndrome, cystic pheochromocytomas may not produce these.
  • [MeSH-minor] Adult. Female. Hepatectomy. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Nephrectomy. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18853034.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


16. Hu YH, Li J: [Clear cell carcinoma of salivary gland: a clinicopathologic study of 10 cases]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2005 Jan;40(1):54-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopically, the tumors were predominantly composed of trabeculae, cords, nests, solid sheets of clear cells and a few eosinophilic cells, and the two kinds of tumor cells were surrounded by hyalinized stroma.
  • CONCLUSIONS: CCC is a distinctive low grade malignant salivary gland neoplasm, arising mainly in the minor salivary glands, and it may originate from intercalated-duct reserve cells.
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15774154.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


17. Campara M, Tzvetanov IG, Oberholzer J: Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation. Expert Opin Biol Ther; 2010 Jun;10(6):959-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation.
  • AREAS COVERED IN THIS REVIEW: This review will update the reader on recently published daclizumab studies in adult solid organ transplant recipients, focusing on comparative studies with other induction agents.
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Heart Transplantation / immunology. Humans. Immunoglobulin G / therapeutic use. Intestines / transplantation. Kidney Transplantation / immunology. Liver Transplantation / immunology. Lung Transplantation / immunology. Recombinant Fusion Proteins / therapeutic use

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20415630.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Interleukin-2; 0 / Recombinant Fusion Proteins; 0 / basiliximab; 3A189DH42V / alemtuzumab; CUJ2MVI71Y / daclizumab
  • [Number-of-references] 49
  •  go-up   go-down


18. Lin CC, Calvo E, Papadopoulos KP, Patnaik A, Sarantopoulos J, Mita AC, Preston GG, Mita MM, Rodon J, Mays T, Yeh IT, O'Rourke P, Takimoto CH, Dancey JE, Chen H, Tolcher AW: Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol; 2009 May;63(6):1065-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Bevacizumab. Cetuximab. Drug Administration Schedule. Erlotinib Hydrochloride. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness. Quinazolines / administration & dosage. Quinazolines / adverse effects. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. Treatment Outcome. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795291.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01-CA069853
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


19. Zushi Y, Noguchi K, Hashitani S, Sakurai K, Segawa E, Takaoka K, Toyohara Y, Tanaka N, Kishimoto H, Urade M: Relations among expression of CXCR4, histological patterns, and metastatic potential in adenoid cystic carcinoma of the head and neck. Int J Oncol; 2008 Dec;33(6):1133-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate the involvement of chemokines in metastasis from ACC, expression of CXCR4 in surgical specimens of ACC and two tumor lines transplantable to nude mice was examined immunohistochemically.
  • ACCs showing a solid or cribriform pattern with distant metastasis were strongly positive for CXCR4, while those showing a tubular or cribriform pattern without metastasis were weakly positive for CXCR4.
  • In the in vivo model, ACCY tumor showed increasing expression levels of CXCR4 with tumor growth, and the histological pattern changed from cribriform to solid.
  • This tumor showed high levels of CXCR4 protein and mRNA.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / immunology. Head and Neck Neoplasms / immunology. Lung Neoplasms / immunology. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Blotting, Western. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Mice. Mice, Nude. Middle Aged. Neoplasm Staging. Neoplasm Transplantation. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020745.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCR4 protein, human; 0 / RNA, Messenger; 0 / Receptors, CXCR4
  •  go-up   go-down


20. Mishunina TM, Kalinichenko OV, Tronko MD, Statsenko OA: Caspase-3 activity in papillary thyroid carcinomas. Exp Oncol; 2010 Dec;32(4):269-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: At initial stages of tumor development, in the absence of metastases to lymph nodes, blood and lymphatic vessel invasion by tumor cells, extrathyroid spreading of tumor, sclerotic and fibrous changes in tumor stroma, and in the presence of tumor capsule, caspase-3 activity in papillary carcinoma tissue was higher compared to unchanged thyroid tissue of normofollicular structure.
  • In case of a more aggressive behaviour of tumor, enzyme activity in carcinoma tissue did not differ significantly or (in case of extrathyroid spreading of tumor) was decreased compared to that in extratumoral tissue.
  • In combination, this was expressed by a progressive decrease in caspase-3 activity in tumor tissue with increasing T category.
  • Сaspase 3 activity was found to be much higher in the tissue of papillary carcinomas of follicular-papillary structure and lower in the tissue of tumors of mixed structure with solid areas, compared to that in the tissue of papillary carcinomas of typical papillary structure.
  • [MeSH-minor] Adult. Apoptosis / physiology. Carcinoma. Female. Humans. Male. Neoplasm Staging. Prognosis. Thyroid Neoplasms / enzymology. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21270757.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; Thyroid cancer, papillary
  •  go-up   go-down


21. Bloom D, Chang Z, Pauly K, Kwun J, Fechner J, Hayes C, Samaniego M, Knechtle S: BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant; 2009 Aug;9(8):1835-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAFF is increased in renal transplant patients following treatment with alemtuzumab.
  • Alemtuzumab is a monoclonal antibody that depletes T and B cells and is used as induction therapy for renal transplant recipients.
  • Without long-term calcineurin inhibitor (CNI) therapy, alemtuzumab-treated patients have a propensity to develop alloantibody and may undergo antibody-mediated rejection (AMR).
  • In pursuit of a mechanistic explanation, we analyzed peripheral B cells and serum of these patients for BAFF (Blys) and BAFF-R, factors known to be integral for B-cell activation, survival, and homeostasis.
  • Serum BAFF levels of 22/24 alemtuzumab-treated patients were above normal range, with average levels of 1967 pg/mL compared to 775 pg/mL in healthy controls (p = 0.006).
  • BAFF remained elevated 2 years posttransplant in 78% of these patients.
  • BAFF-R on CD19(+) B cells was significantly downregulated, suggesting ligand/receptor engagement.
  • BAFF mRNA expression was increased 2-7-fold in CD14(+) cells of depleted patients, possibly linking monocytes to the BAFF dysregulation.
  • Addition of recombinant BAFF to mixed lymphocyte cultures increased B-cell activation to alloantigen, as measured by CD25 and CD69 coexpression on CD19(+) cells.
  • Of note, addition of sirolimus (SRL) augmented BAFF-enhanced B-cell activation whereas CNIs blocked it.
  • These data suggest associations between BAFF/BAFF-R and AMR in alemtuzumab-treated patients.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522878.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI050938; United States / NIDDK NIH HHS / DK / T35 DK062709; United States / NIAID NIH HHS / AI / R01 AI050938-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / B-Cell Activating Factor; 0 / B-Cell Maturation Antigen; 0 / CD69 antigen; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Lectins, C-Type; 0 / TNFRSF13B protein, human; 0 / TNFRSF17 protein, human; 0 / TNFSF13B protein, human; 0 / Transmembrane Activator and CAML Interactor Protein; 0 / Tumor Necrosis Factor Ligand Superfamily Member 13; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ NIHMS783838; NLM/ PMC4876605
  •  go-up   go-down


22. Muro K, Yoshino T, Doi T, Shirao K, Takiuchi H, Hamamoto Y, Watanabe H, Yang BB, Asahi D: A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol; 2009 May;39(5):321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible patients had histologically proven colorectal adenocarcinoma and EGFR tumor expression in > or =1% of tumor cells by immunohistochemistry.
  • The primary endpoint was objective response rate (ORR) per modified Response Evaluation Criteria in Solid Tumors (RECIST) by independent central review.
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asian Continental Ancestry Group. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Female. Humans. Immunohistochemistry. Japan. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Pyrimidines / administration & dosage. Receptor, Epidermal Growth Factor / analysis


23. Laspas F, Roussakis A, Papadopoulos S, Fanariotis I, Kritikos N, Kehagias D: Mixed tumor of the vagina: sonographic and magnetic resonance imaging findings. Ultrasound Obstet Gynecol; 2010 May;35(5):617-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed tumor of the vagina: sonographic and magnetic resonance imaging findings.
  • Mixed tumor of the vagina is a rare benign neoplasm that is composed of epithelial and mesenchymal cells.
  • The majority of tumors are asymptomatic and simple tumor excision is curative.
  • The lesion was well defined, solid and showed diffuse hypervascularity on color flow images.
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Prognosis

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 20069660.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Jiao YF, Sugai T, Habano W, Uesugi N, Takagane A, Nakamura S: Clinicopathological significance of loss of heterozygosity in intestinal- and solid-type gastric carcinomas: a comprehensive study using the crypt isolation technique. Mod Pathol; 2006 Apr;19(4):548-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of loss of heterozygosity in intestinal- and solid-type gastric carcinomas: a comprehensive study using the crypt isolation technique.
  • We and other researchers have previously demonstrated that LOH is fairly common in intestinal- and solid-type gastric carcinomas, but rare in diffuse-type tumors.
  • In this study, we investigated the relationship between clinicopathological variables and LOH status in intestinal- and solid-type gastric carcinomas.
  • The crypt isolation technique was utilized to analyze LOH at 1p36, 3p14, 4p15, 5q21-22, 8p11-12, 9p21, 13q22, 17p13.1 18q21 and 22q13.31 in 113 intestinal- and solid-type gastric carcinomas using a polymerase chain reaction assay.
  • These results suggest that in intestinal- and solid-type gastric carcinomas, LOH on 3p14, 4p15, 5q21-22, 9p21, 13q22 and 18q21 is associated with carcinogenesis, while LOH on 1p36, 8p11-12, 17p31.1 and 22q13.31 is associated with tumor progression.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Lymphatic Metastasis. Male. Microsatellite Repeats. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474377.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V: Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Res; 2006;8(4):R36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.
  • METHODS: The medical files of patients with early breast cancer (n = 253) or advanced stage breast cancer (n = 239) as well of those with other solid tumors (n = 336) treated with or without a taxane-based chemotherapy regimen during a 42-month period were reviewed.
  • HER2/neu overexpression was identified by immunohistochemistry, whereas cytokeratin 19 (CK-19) mRNA-positive circulating tumor cells (CTCs) in the peripheral blood were identified by real-time PCR.
  • RESULTS: The incidence of CNS relapse was similar in patients suffering from breast cancer or other solid tumors (10.4% and 11.4%, respectively; P = 0.517).
  • CONCLUSION: CNS relapses are common among breast cancer patients treated with a taxane-based chemotherapy regimen, patients with HER2/neu-positive tumor and patients with CK-19 mRNA-positive CTCs.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Keratin-19. Middle Aged. Neoplasm Staging. Predictive Value of Tests. RNA, Messenger. Receptor, ErbB-2 / biosynthesis. Taxoids / therapeutic use


26. Diallo R, Rody A, Jackisch C, Ting E, Schaefer KL, Kissler S, Karn T, Geddert H, Engels K, Kaufmann M, Gabbert HE, Shroyer KR, Poremba C: C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu. Hum Pathol; 2006 Feb;37(2):205-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • C-KIT expression was found in 55 (52.8%) of all DCIS, correlating with high nuclear grade (P < .0001), comedonecrosis (P < .0001), and solid growth pattern (P = .001).
  • Our findings suggest that the expression of c-KIT protein might define a subset of poorly differentiated, HER-2-positive DCIS with decreased expression of steroid hormone receptors, comedonecrosis, and a solid growth pattern.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Neoplasm Invasiveness. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426921.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


27. Génébès C, Brouchet L, Kamar N, Lepage B, Prévot G, Rostaing L, Didier A, Mazières J: Characteristics of thoracic malignancies that occur after solid-organ transplantation. J Thorac Oncol; 2010 Nov;5(11):1789-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of thoracic malignancies that occur after solid-organ transplantation.
  • BACKGROUND: Chronic immunosuppression after solid-organ transplantation is associated with increased risk of developing malignancies.
  • The purpose of this study was to determine the clinical characteristics and the outcome of thoracic malignancies in patients who have undergone solid-organ transplantation.
  • CONCLUSION: Solid-organ transplantation is associated with a high risk of lung cancer and may have an important synergetic part with other risk factors for lung cancer (tobacco).
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate


28. Bostanoglu S, Otan E, Akturan S, Hamamci EO, Bostanoglu A, Gokce A, Albayrak L: Frantz's tumor (solid pseudopapillary tumor) of the pancreas. A case report. JOP; 2009;10(2):209-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frantz's tumor (solid pseudopapillary tumor) of the pancreas. A case report.
  • CONTEXT: A solid pseudopapillary tumor of the pancreas is a rare neoplasm which, for the most part, affects young women and has a relatively favorable prognosis with a low malignant potential.
  • CASE REPORT: We report the case of a 29-year-old woman who underwent complete resection of the tumor using a distal pancreatectomy and splenectomy procedure.
  • CONCLUSIONS: A solid pseudopapillary tumor of the pancreas is a rare condition with a low potential for malignancy and favorable prognosis; surgical resection is generally curative.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Pancreatectomy / methods. Prognosis. Splenectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287121.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


29. Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS, Miller JS: First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res; 2007 Dec 1;13(23):7119-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Eligible adult patients with refractory solid organ tumors received i.v.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line. Cohort Studies. Cytokines / immunology. Dendritic Cells / drug effects. Dendritic Cells / immunology. Drug Administration Schedule. Female. Humans. Immunity, Innate / drug effects. Male. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056192.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / N-(4-(4-amino-2-ethyl-1H-imidazo(4,5c)quinolin-1-yl)butyl)methanesulfonamide; 0 / Quinolines; 0 / Sulfonamides; 0 / TLR7 protein, human; 0 / Toll-Like Receptor 7
  •  go-up   go-down


30. Adamski H, Le Lan J, Chevrier S, Cribier B, Watier E, Chevrant-Breton J: Primary cutaneous cribriform carcinoma: a rare apocrine tumour. J Cutan Pathol; 2005 Sep;32(8):577-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This neoplasm is often located on the limbs.
  • The cells were arranged in solid nests or tubular structures.
  • [MeSH-minor] Adult. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115058.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


31. Silverman SG, Gan YU, Mortele KJ, Tuncali K, Cibas ES: Renal masses in the adult patient: the role of percutaneous biopsy. Radiology; 2006 Jul;240(1):6-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal masses in the adult patient: the role of percutaneous biopsy.
  • Because a considerable fraction of small solid renal masses are benign and do not need treatment, there is an increasing need to diagnose them.
  • [MeSH-minor] Adult. Humans. Neoplasm Staging / methods


32. Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A: Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety. Cancer Chemother Pharmacol; 2008 Jun;62(1):97-109
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
  • METHODS: Patients (n = 30) with advanced malignant HER2 positive solid tumors were enrolled in this open label dose-escalation study, and treated with daily oral dosing of CP-724,714 in 21-day cycles at the following dose levels: 250 mg QD, 250 mg BID, 400 mg BID, and 250 mg TID.
  • [MeSH-minor] Adult. Aged. Algorithms. Area Under Curve. Breast Neoplasms / drug therapy. Chromatography, Liquid. Dose-Response Relationship, Drug. Drug-Induced Liver Injury / epidemiology. Drug-Induced Liver Injury / pathology. Female. Half-Life. Humans. Liver Function Tests. Middle Aged. Neoplasm Metastasis / drug therapy. Tandem Mass Spectrometry

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805538.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 2-methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


33. Carrasco Ortiz D, Aldape Barrios B: Adenoid cystic carcinoma of the dorsum of the tongue: presentation of a case. Med Oral Patol Oral Cir Bucal; 2006 Aug;11(5):E417-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenoid cystic carcinoma is the most frequent malignant neoplasm of minor salivary glands (76.5%); it is clinically characterized by slow growth, and its most frequent localization is the hard palate.
  • Histopathologically it presents three patterns, cribriform, tubular and solid; the solid type is related to a poor prognostic contrary to the cribriform type, which has a better prognosis.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Humans. Male

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878059.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


34. Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA: Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol; 2010 Oct;5(10):1623-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pretreatment tumor specimens were collected for mutation testing.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Trials, Phase I as Topic. Cohort Studies. Everolimus. Female. Humans. Male. Middle Aged. Mutation / genetics. Neoplasm Staging. Proto-Oncogene Proteins / genetics. Quinazolines / administration & dosage. Receptor, Epidermal Growth Factor / genetics. Salvage Therapy. Sirolimus / administration & dosage. Sirolimus / analogs & derivatives. Survival Rate. Treatment Outcome. ras Proteins / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Thorac Oncol. 2012 May;7(5):919-22 [22722792.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2316-26 [12796401.001]
  • [Cites] Oncologist. 2003;8(4):303-6 [12897327.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] N Engl J Med. 1987 Oct 8;317(15):929-35 [3041218.001]
  • [Cites] Oncogene. 1990 Jul;5(7):1037-43 [2197591.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2053-9 [15240509.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3226-35 [15833854.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1711-9 [15870831.001]
  • [Cites] PLoS Med. 2005 Jan;2(1):e17 [15696205.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(11):1649-54 [15994075.001]
  • [Cites] Nature. 2005 Aug 11;436(7052):792 [16094359.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):315-23 [16397245.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1875-80 [16806903.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2695-706 [16906227.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):599-605 [17577220.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2255-9 [18224685.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3065-74 [18725988.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7409-18 [18794129.001]
  • [Cites] Cancer Biol Ther. 2008 Dec;7(12):1952-8 [18981735.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3256-61 [19351834.001]
  • [Cites] Biochem Pharmacol. 2009 Sep 1;78(5):460-8 [19427302.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] Ann Oncol. 2009 Oct;20(10):1674-81 [19549709.001]
  • [Cites] Oncogene. 2003 May 8;22(18):2812-22 [12743604.001]
  • (PMID = 20871262.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121210
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; 9HW64Q8G6G / Everolimus; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; S65743JHBS / gefitinib; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS578877; NLM/ PMC4020424
  •  go-up   go-down


35. Kudla MJ, Timor-Tritsch IE, Hope JM, Monteagudo A, Popiolek D, Monda S, Lee CJ, Arslan AA: Spherical tissue sampling in 3-dimensional power Doppler angiography: a new approach for evaluation of ovarian tumors. J Ultrasound Med; 2008 Mar;27(3):425-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calculations for the whole solid volume were done for comparison.
  • Spherical 1-cm3 sampling achieved a higher degree of discrimination between the groups compared with the whole solid-part approach.
  • [MeSH-minor] Adult. Case-Control Studies. Diagnosis, Differential. Female. Humans. Image Interpretation, Computer-Assisted. Neoplasm Invasiveness. Retrospective Studies. Sensitivity and Specificity. Software. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18314521.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


36. Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies AF, Faivre S, Moxhon A, Duprez T, Guigay J: Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol; 2010 Jan 1;28(1):21-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The volume transfer constant of the contrast agent (K(trans)) was used to measure changes in the microcirculation blood flow and endothelial permeability of the tumor.
  • Results A PR was observed in one patient, SD in 18, and PD in 19 (Response Evaluation Criteria in Solid Tumors [RECIST]), resulting in a disease control rate of 50%.
  • Local complications, including the appearance or worsening of tumor skin ulceration or tumor fistula, were recorded in 15 patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Indoles / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Angiography. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917865.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  •  go-up   go-down


37. Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M: Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol; 2010 Nov;136(11):1729-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Single center data on characteristics, treatment and outcome of 135 consecutive pts (73 solid tumors and 62 hematologic malignancies) with LM between 1989 and 2005 were retrospectively analyzed.
  • Univariate analysis revealed age >50, interval between diagnosis of primary tumor and LM ≤12 months, lung cancer and malignant melanoma, and Karnofsky performance status ≤70 as significant negative predictors for overall survival.
  • CONCLUSIONS: In patients with LM an age >50, performance status ≤70%, interval between diagnosis of primary tumor and LM ≤12 months, primary tumor (lung cancer, malignant melanoma) and lack of cytologic response present negative prognostic factors.
  • [MeSH-major] Meningeal Carcinomatosis / pathology. Neoplasm Metastasis / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Hematologic Neoplasms / drug therapy. Hematologic Neoplasms / mortality. Hematologic Neoplasms / pathology. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / mortality. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Male. Melanoma / drug therapy. Melanoma / mortality. Melanoma / pathology. Melanoma / radiotherapy. Middle Aged. Neoplasms / drug therapy. Neoplasms / mortality. Neoplasms / pathology. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Sci. 2004 Aug 30;223(2):167-78 [15337619.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2726-33 [15571954.001]
  • [Cites] Curr Opin Oncol. 2006 Nov;18(6):637-43 [16988587.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1315-23 [8608509.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):561-9 [8445432.001]
  • [Cites] Cancer Invest. 2005;23(2):145-54 [15813508.001]
  • [Cites] Neurology. 1994 Aug;44(8):1463-9 [8058150.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):255-60 [16344918.001]
  • [Cites] Expert Opin Pharmacother. 2005 Jun;6(7):1115-25 [15957966.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2640-7 [17960791.001]
  • [Cites] J Neurooncol. 1997 Oct;35(1):55-64 [9266441.001]
  • [Cites] Jpn J Clin Oncol. 2003 Dec;33(12):608-12 [14769837.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1561-7 [9552066.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):107-17 [17332946.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):199-207 [18287337.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3110-6 [10506606.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):57-62 [17310266.001]
  • [Cites] Cancer. 1998 May 1;82(9):1756-63 [9576299.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3605-13 [15908671.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • (PMID = 20204406.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Chang IW, Huang HY, Sung MT: Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts. Am J Surg Pathol; 2009 Dec;33(12):1894-901
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Melanotic Xp11 translocation renal cancer is a recently recognized aggressive epithelioid neoplasm with features overlapping between PEComa, carcinoma, and melanoma.
  • The tumor was composed of solid nests of epithelioid cells bearing abundant clear to finely granular eosinophilic cytoplasm and separated by delicate vascular septa.
  • Finely granular and nonrefractile brown melanin pigments, highlighted by Fontana-Masson stain, were scattered through the tumor.
  • By immunohistochemistry, the tumor was diffusely and strongly labeled by TFE3 and focally stained by HMB45 in a patchy pattern.
  • In contrast, all other applied immunomarkers, including cytokeratins, epithelial membrane antigen, vimentin, CD10, S-100, smooth muscle actin, desmin, c-kit, CD68, and microphthalmia-associated transcription factor, were nonreactive to the tumor.
  • Up-regulations of melanogenesis-associated regulators, including microphthalmia-associated transcription factor, tyrosinase (TYR), and tyrosinase-related protein 1 (TYRP1), were identified in the tumor by semiquantitative reverse transcription-polymerase chain reaction.
  • The morphologic and immunohistochemical discrepancies between this intriguing melanotic tumor and other documented renal cell carcinomas bearing identical PSF-TFE3 gene fusion may suggest melanotic Xp11 translocation renal cancer is a distinct entity among the MiT/TFE family neoplasms.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. DNA Mutational Analysis. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Membrane Glycoproteins / genetics. Microphthalmia-Associated Transcription Factor / genetics. Middle Aged. Monophenol Monooxygenase / genetics. Oxidoreductases / genetics. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19809274.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / MITF protein, human; 0 / Melanins; 0 / Membrane Glycoproteins; 0 / Microphthalmia-Associated Transcription Factor; 0 / PTB-associated splicing factor; 0 / RNA-Binding Proteins; 0 / TFE3 protein, human; EC 1.- / Oxidoreductases; EC 1.14.18.- / TYRP1 protein, human; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


39. Dodd LG: Fine-needle aspiration of chondrosarcoma. Diagn Cytopathol; 2006 Jun;34(6):413-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine-needle aspiration (FNA) is a reliable, safe and cost-effective procedure with an established role in the diagnosis of various solid tissue neoplasms.
  • Of the primary CS, 18 were definitively diagnosed as CS or "malignant chondroid neoplasm," 8 of the aspirates were considered equivocal in that an additional diagnostic procedure was required to clarify or confirm the diagnosis.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity


40. Ladetto M, Vallet S, Trojan A, Dell'Aquila M, Monitillo L, Rosato R, Santo L, Drandi D, Bertola A, Falco P, Cavallo F, Ricca I, De Marco F, Mantoan B, Bode-Lesniewska B, Pagliano G, Francese R, Rocci A, Astolfi M, Compagno M, Mariani S, Godio L, Marino L, Ruggeri M, Omedè P, Palumbo A, Boccadoro M: Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood; 2005 Jun 15;105(12):4784-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclooxygenase 2 (COX-2) is an inflammation-associated enzyme involved in the pathogenesis of many solid tumors, but little is known about its presence and role in hematologic neoplasms.
  • We thus decided to investigate the involvement of COX-2 in this neoplasm.
  • [MeSH-minor] Adult. Aged. Blotting, Western. Bone Marrow Cells / cytology. Bone Marrow Cells / metabolism. Cell Line, Tumor. Cyclooxygenase 2. DNA, Complementary / metabolism. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry. Inflammation. Male. Membrane Glycoproteins / biosynthesis. Membrane Proteins. Middle Aged. Prognosis. Proteoglycans / biosynthesis. RNA, Messenger / metabolism. Recurrence. Reverse Transcriptase Polymerase Chain Reaction. Syndecan-1. Syndecans. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15731178.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


41. Luo DL, Liu YH, Zhuang HG, Liao RQ, Luo XL, Xu FP, Zhang F: [Clinicopathologic study of pulmonary adenocarcinoma with features of bronchioloalveolar carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Nov;37(11):737-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent one was adenocarcinoma of mixed subtypes (78.2%, 272/348), followed by the acinar type (8.1%, 28/348), the papillary type (4.0%, 14/348), the BAC (3.7%, 13/348), the mucinous (colloid) type (3.4%, 12/348) and the solid types (2.3%, 8/348).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lung / pathology. Male. Middle Aged. Neoplasm Staging / methods. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094707.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Wijffels KI, Hoogsteen IJ, Lok J, Rijken PF, Marres HA, de Wilde PC, van der Kogel AJ, Kaanders JH: No detectable hypoxia in malignant salivary gland tumors: preliminary results. Int J Radiat Oncol Biol Phys; 2009 Apr 1;73(5):1319-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Hypoxia is detected in most solid tumors and is associated with malignant progression and adverse treatment outcomes.
  • The aim of this study was to investigate the potential clinical relevance of hypoxia in this tumor type.
  • METHODS AND MATERIALS: Twelve patients scheduled for surgical resection of a salivary gland tumor were preoperatively injected with the hypoxia marker pimonidazole and the proliferation marker iododeoxyuridine.
  • Tissue samples of the dissected tumor were immunohistochemically stained for blood vessels, pimonidazole, carbonic anhydrase-IX, glucose transporters-1 and -3 (Glut-1, Glut-3), hypoxia-inducible factor-1alpha, iododeoxyuridine, and epidermal growth factor receptor.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / analysis. Carbonic Anhydrases / analysis. Cell Proliferation. Deoxyuridine / analogs & derivatives. Glucose Transporter Type 1 / analysis. Glucose Transporter Type 2 / analysis. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / analysis. Middle Aged. Nitroimidazoles / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18973979.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Glucose Transporter Type 1; 0 / Glucose Transporter Type 2; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nitroimidazoles; 46JO4D76R2 / pimonidazole; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; W78I7AY22C / Deoxyuridine
  •  go-up   go-down


43. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, Boven E: Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer; 2010 Mar 2;102(5):803-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At first evaluation, according to the Response Evaluation Criteria in Solid Tumours (RECIST) 7 patients had PR, 38 stable disease (SD), and 10 progressive disease (PD), whereas according to Choi criteria 36 patients had PR, 6 SD and 13 PD.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1760-4 [17470866.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1753-9 [17470865.001]
  • [Cites] Int J Urol. 2007 Dec;14(12):1095-7; discussion 1097 [18036049.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2011-9 [18083403.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):152-4 [18165649.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2431-6 [18413834.001]
  • [Cites] Br J Cancer. 2008 Jul 22;99(2):259-65 [18594533.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:2248-68 [19273199.001]
  • [Cites] World J Urol. 2009 Aug;27(4):533-9 [19145434.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):289-96 [11773181.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):118-23 [15797301.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):747s-752s [17255304.001]
  • [Cites] Lancet Oncol. 2007 Nov;8(11):975-84 [17959415.001]
  • (PMID = 20145618.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  • [Other-IDs] NLM/ PMC2833256
  •  go-up   go-down


44. Hwang SS, Choi HJ, Park SY: Cavernous mesenteric lymphangiomatosis mimicking metastasis in a patient with rectal cancer: a case report. World J Gastroenterol; 2009 Aug 21;15(31):3947-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Typically, lymphangioma appears on computed tomography (CT) as a lower attenuation of a cystic mass, however, some cases appear to be a solid mass.
  • We describe the CT and 18F-FDG positron emission tomography/CT appearance in a case of jejunal and mesenteric cavernous lymphangiomatosis mimicking metastasis in an adult patient with rectal cancer.
  • [MeSH-minor] Aged. Child. Diagnosis, Differential. Humans. Intestinal Neoplasms / pathology. Intestinal Neoplasms / radiography. Jejunum / pathology. Jejunum / radiography. Male. Neoplasm Metastasis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lymphangiomatosis.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2000;6(2):146-8 [10936792.001]
  • [Cites] Thorax. 1994 Dec;49(12):1267-8 [7878566.001]
  • [Cites] Eur J Radiol. 1995 Mar;19(3):183-7 [7601168.001]
  • [Cites] Am J Gastroenterol. 1997 Sep;92(9):1566-7 [9317093.001]
  • [Cites] J Gastroenterol. 1998 Feb;33(1):107-11 [9497231.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2150-8 [9610694.001]
  • [Cites] Curr Probl Diagn Radiol. 2008 Jul-Aug;37(4):178-88 [18502325.001]
  • [Cites] World J Gastroenterol. 2005 Aug 28;11(32):5084-6 [16124074.001]
  • [Cites] Abdom Imaging. 2005 Sep-Oct;30(5):605-9 [15723180.001]
  • [Cites] World J Surg. 2005 Jul;29(7):837-40 [15951926.001]
  • [Cites] Minerva Chir. 2006 Dec;61(6):529-32 [17211360.001]
  • [Cites] Lymphat Res Biol. 2007;5(4):269-73 [18370918.001]
  • [Cites] J Korean Med Sci. 1999 Jun;14(3):257-62 [10402167.001]
  • (PMID = 19701979.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2731261
  •  go-up   go-down


45. Ji Y, Zhu XZ, Lou WH, Wang DQ, Jin DY, Zeng MS, Zeng HY: [Clinicopathologic analysis of 92 cases of pancreatic cystic neoplasm]. Zhonghua Bing Li Xue Za Zhi; 2007 Mar;36(3):160-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of 92 cases of pancreatic cystic neoplasm].
  • METHODS: Ninety-two cases of cystic neoplasm of pancreas were retrieved from the Department archival file during the period from 1999 to 2005.
  • They consisted of intraductal papillary mucinous neoplasm (36/92), serous cystic neoplasm (18/92), solid pseudopapillary tumor (18/92), mucinous cystic neoplasm (14/92), cystic pancreatic ductal adenocarcinoma (4/92) and cystic pancreatic endocrine neoplasm (2/92).
  • Immunohistochemical study revealed variable staining patterns, with frequent overlaps between different tumor types.
  • In general, serous cystic neoplasm expressed MUC1, while mucinous cystic neoplasm was positive for MUC-5AC, intraductal papillary mucinous neoplasm for MUC-2 and cystic pancreatic ductal adenocarcinoma for MUC-1.
  • On the other hand, solid pseudopapillary tumor expressed alpha-antitrypsin, alpha-antichymotrypsin, vimentin and progesterone receptor.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Mucin 5AC / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535681.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1
  •  go-up   go-down


46. Mohanty SK, Parwani AV: Mixed epithelial and stromal tumors of the kidney: an overview. Arch Pathol Lab Med; 2009 Sep;133(9):1483-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mixed epithelial and stromal tumor of the kidney is a recently recognized distinct neoplasm that should be distinguished from other renal neoplasms.
  • Imaging studies are not diagnostic but reveal a solid or solid and cystic mass in most cases.
  • This article provides a brief overview of the current knowledge of mixed epithelial and stromal tumor of the kidney.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Diagnosis, Differential. Female. Fibroma / diagnosis. Humans. Male. Middle Aged. Nephroma, Mesoblastic / diagnosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Stromal Cells / metabolism. Stromal Cells / pathology. Translocation, Genetic. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722760.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Number-of-references] 28
  •  go-up   go-down


47. Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG, Pilotti S: Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther; 2010 May;9(5):1286-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
  • Antiangiogenic treatment activity has been reported in solitary fibrous tumor (SFT), a rare and little chemosensitive sarcoma.
  • The best response according to the Choi criteria was six partial response (all with Response Evaluation Criteria in Solid Tumors stable disease), one stable disease, and three progressive disease.
  • A Response Evaluation Criteria in Solid Tumors partial response to figitumumab corroborated these findings.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / genetics. Indoles / administration & dosage. Pyrroles / administration & dosage. Solitary Fibrous Tumors / drug therapy
  • [MeSH-minor] Adult. Aged. Biomarkers, Pharmacological / analysis. Biomarkers, Pharmacological / metabolism. Disease Progression. Drug Administration Schedule. Drug Resistance, Neoplasm / genetics. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunoglobulins, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Receptor, Platelet-Derived Growth Factor beta / genetics. Receptor, Platelet-Derived Growth Factor beta / metabolism. Tomography, X-Ray Computed. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20457621.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Pharmacological; 0 / Biomarkers, Tumor; 0 / Immunoglobulins, Intravenous; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; VE267FC2UB / figitumumab
  •  go-up   go-down


48. Guérin S, Guibout C, Shamsaldin A, Dondon MG, Diallo I, Hawkins M, Oberlin O, Hartmann O, Michon J, Le Deley MC, de Vathaire F: Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: a case-control study. Int J Cancer; 2007 Jan 1;120(1):96-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: a case-control study.
  • Radiotherapy and chemotherapy are associated with an increased risk of a second malignant neoplasm (SMN) after a cancer during childhood.
  • A case-control study nested in a European cohort of 4,581 patients treated for a solid cancer during childhood was conducted.
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Child. Child, Preschool. Combined Modality Therapy. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy Dosage. Risk Factors


49. El-Bahrawy MA, Rowan A, Horncastle D, Tomlinson I, Theis BA, Russell RC, Stamp G: E-cadherin/catenin complex status in solid pseudopapillary tumor of the pancreas. Am J Surg Pathol; 2008 Jan;32(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E-cadherin/catenin complex status in solid pseudopapillary tumor of the pancreas.
  • Solid pseudopapillary tumor (SPT) of the pancreas is an uncommon neoplasm of uncertain lineage.
  • [MeSH-minor] Adult. DNA Mutational Analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2008 Aug;32(8):1269-70 [18594465.001]
  • (PMID = 18162763.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


50. Jang HW, Park WK, Chang JC, Kim JW, Bae YK, Choi JH, Yun SS, Lee DS: [Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas]. Korean J Gastroenterol; 2006 Nov;48(5):355-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Undifferentiated carcinoma with osteoclast-like giant cells is a rare neoplasm of exocrine pancreas.
  • On computed tomography, one case showed a well enhancing solid tumor with low density and the other was showed a mainly cystic tumor with peripheral enhancement in the body and tail of the pancreas.
  • Tumor staining was seen on angiography.
  • In one case, there were small foci of adenocarcinoma components in the periphery of the tumor.
  • [MeSH-minor] Adult. Aged. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132925.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


51. Rütten A, Kutzner H, Mentzel T, Hantschke M, Eckert F, Angulo J, Rodríguez Peralto JL, Requena L: Primary cutaneous cribriform apocrine carcinoma: a clinicopathologic and immunohistochemical study of 26 cases of an under-recognized cutaneous adnexal neoplasm. J Am Acad Dermatol; 2009 Oct;61(4):644-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous cribriform apocrine carcinoma: a clinicopathologic and immunohistochemical study of 26 cases of an under-recognized cutaneous adnexal neoplasm.
  • BACKGROUND: Cribriform carcinoma is the histopathologic variant of cutaneous apocrine carcinoma characterized by interconnected solid aggregations of neoplastic cells that are punctuated by small round spaces.
  • OBJECTIVE: To describe the histopathologic and immunohistochemical characteristics of this under-recognized cutaneous adnexal neoplasm.
  • Histopathologically, the neoplasms consisted of well-circumscribed dermal nodules composed of multiple, interconnected, solid aggregations of basophilic epithelial cells that were punctuated by small round spaces.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Neoplasms, Adnexal and Skin Appendage / metabolism. Neoplasms, Adnexal and Skin Appendage / pathology
  • [MeSH-minor] Adult. Aged. Apocrine Glands / pathology. Biopsy. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Cytoplasm / pathology. Cytoplasm / ultrastructure. Diagnosis, Differential. Epithelial Cells / pathology. Epithelial Cells / ultrastructure. Female. Humans. Immunohistochemistry. Male. Microscopy, Electron. Microvilli / pathology. Microvilli / ultrastructure. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2011 Mar;64(3):599-601 [21315957.001]
  • (PMID = 19751882.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


52. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C: A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res; 2006 Oct 15;12(20 Pt 1):6087-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: A phase I dose escalating trial in patients with advanced solid tumors was done.
  • Toxicity and tumor responses were evaluated by standard criteria.
  • [MeSH-minor] Adult. HSP70 Heat-Shock Proteins / drug effects. HSP70 Heat-Shock Proteins / metabolism. Humans. Infusions, Intravenous. Life Expectancy. Neoplasm Staging. Patient Selection

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062684.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA15083; United States / NCI NIH HHS / CA / CA69912; United States / NCI NIH HHS / CA / CA90390; United States / NCRR NIH HHS / RR / RR00585
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP70 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 4GY0AVT3L4 / tanespimycin
  •  go-up   go-down


53. Bhardwaj N, Strickland AD, Ahmad F, El-Abassy M, Morgan B, Robertson GS, Lloyd DM: Microwave ablation for unresectable hepatic tumours: clinical results using a novel microwave probe and generator. Eur J Surg Oncol; 2010 Mar;36(3):264-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new microwave generator and probe, designed to deliver high energy into solid tumours quickly has been developed at our institution.
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Great Britain / epidemiology. Humans. Incidence. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Survival Rate / trends. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19880269.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Lim B, Smith A, Chandu A: Treatment of oral leukoplakia with carbon dioxide and potassium-titanyl-phosphate lasers: a comparison. J Oral Maxillofac Surg; 2010 Mar;68(3):597-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Lasers, Gas / therapeutic use. Lasers, Solid-State / therapeutic use. Leukoplakia, Oral / surgery. Mouth Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Leukoplakia.
  • Genetic Alliance. consumer health - Oral leukoplakia.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright (c) 2010. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20171477.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Kinkor Z, Hes O: [Pleomorphic epithelioid/clear cell malignant tumor of the uterus exhibiting both myoid and melanocytic differentiation--leiomyosarcoma or PEComa? A case report and a review of the literature]. Cesk Patol; 2007 Jul;43(3):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleomorphic epithelioid/clear cell malignant tumor of the uterus exhibiting both myoid and melanocytic differentiation--leiomyosarcoma or PEComa? A case report and a review of the literature].
  • [Transliterated title] Pleomorfni epiteloidni a svetlobunecný maligní tumor delohy s myoidní a melanocytární diferenciací--leiomyosarkom nebo PECom? Kazuistika a prehled literatury.
  • The neoplasm broadly invaded myometrium with no evidence of endometrial cavity involvement.
  • Microscopically, the tumor displayed solid mosaic pattern and consisted of large epithelioid cells with ample eosinophilic, finely granular cytoplasm ongoing apparent clear cell change elsewhere.
  • With some uncertainty the tumor was finally rendered as pleomorphic leiomyosarcoma with peculiar melanocytic differentiation.
  • [MeSH-minor] Adult. Epithelioid Cells / pathology. Female. Humans


56. Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P, Ritter G, Wiesneth M, Döhner H, Schmitt M: Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia. Blood; 2005 Aug 1;106(3):938-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because RHAMM/CD168 is also expressed in various other hematologic malignancies and solid tumors, vaccines targeting this antigen may have even wider application.
  • [MeSH-minor] Acute Disease. Adult. Aged. Amino Acid Sequence. Antigens, Neoplasm / immunology. Cytotoxicity, Immunologic. Epitope Mapping. Female. Humans. Immunotherapy. Male. Middle Aged. Peptides / chemical synthesis. Peptides / immunology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827130.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Epitopes, T-Lymphocyte; 0 / Extracellular Matrix Proteins; 0 / HLA-A2 Antigen; 0 / Peptides; 0 / hyaluronan-mediated motility receptor
  •  go-up   go-down


57. Yeh TS, Tseng JH, Liu NJ, Chen TC, Jan YY, Chen MF: Significance of cellular distribution of ezrin in pancreatic cystic neoplasms and ductal adenocarcinoma. Arch Surg; 2005 Dec;140(12):1184-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients with solid pseudopapillary tumor (SPT) (n = 12), mucinous cystic neoplasm (MCN) (n = 18), intraductal papillary mucinous tumor (IPMT) (n = 18), and ductal adenocarcinoma (PA) (n = 73) of the pancreas were studied.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Cytoskeletal Proteins. Disease Progression. Epidermal Growth Factor / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. RNA, Messenger / chemistry. Receptor, Epidermal Growth Factor / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365240.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Phosphoproteins; 0 / RNA, Messenger; 0 / ezrin; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


58. Kusumoto H, Haraguchi M, Nozuka Y, Oda Y, Tsuneyoshi M, Iguchi H: Characteristic features of disseminated carcinomatosis of the bone marrow due to gastric cancer: the pathogenesis of bone destruction. Oncol Rep; 2006 Oct;16(4):735-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Disseminated carcinimatosis of the bone marrow is accompanied by solid tumors, and gastric cancer accounts for the majority.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Parathyroid Hormone-Related Protein / biosynthesis. RANK Ligand / biosynthesis. Time Factors

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969487.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; 0 / RANK Ligand
  •  go-up   go-down


59. Machado MC, Machado MA: Solid serous adenoma of the pancreas: an uncommon but important entity. Eur J Surg Oncol; 2008 Jul;34(7):730-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid serous adenoma of the pancreas: an uncommon but important entity.
  • Serous cystic neoplasms of the pancreas have currently five recognized subtypes: serous microcystic adenoma, serous oligocystic ill-demarcated adenoma, solid serous adenoma, von Hippel-Lindau-associated cystic neoplasm, and serous cystadenocarcinoma.
  • Solid serous adenoma of the pancreas is by far the rarest subtype with only nine cases published thus far.
  • After analyzing the literature, including one case from our Department, we can conclude that there is enough evidence to support that solid serous adenomas of the pancreas is a solid variant of serous cystadenomas.
  • Given benign nature of this solid variant conservative surgery is recommended.
  • It is definitively a rare entity but oncologic surgeons should be aware of this neoplasm in order to make a correct preoperative diagnosis that will ultimately result in more conservative surgeries.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440191.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 12
  •  go-up   go-down


60. Bologna-Molina R, Mosqueda-Taylor A, Lopez-Corella E, Almeida OP, Carrasco-Daza D, Garcia-Vazquez F, Farfan-Morales JE, Irigoyen-Camacho ME, Damián-Matsumura P: Syndecan-1 (CD138) and Ki-67 expression in different subtypes of ameloblastomas. Oral Oncol; 2008 Aug;44(8):805-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastoma is the most frequent odontogenic tumor and is considered a benign, but locally invasive, neoplasm with variable clinico-pathological expression.
  • The aims of this study were to examine the pattern of syndecan-1 expression, to evaluate the proliferating activity in a large series of solid/multicystic (SA) and unicystic ameloblastomas (UA), and to study its possible correlation to their biological behavior.
  • [MeSH-major] Ameloblastoma / metabolism. Ki-67 Antigen / metabolism. Neoplasm Proteins / metabolism. Syndecan-1 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Down-Regulation. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Mouth Mucosa / metabolism. Tooth Germ / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207448.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Syndecan-1
  •  go-up   go-down


61. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PE, McArthur G: Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res; 2009 Mar 15;15(6):2123-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ELIGIBILITY CRITERIA: unresectable metastatic melanoma, measurable disease by Response Evaluation Criteria in Solid Tumors, no prior systemic therapy (adjuvant IFN permitted), adequate major organ function, good performance status, no significant autoimmune disease, and life expectancy at least 4 months.
  • Best tumor response included one confirmed CR and one confirmed partial response, both with lung metastases.
  • [MeSH-minor] Adult. Aged. Female. Humans. Interleukin-2 Receptor alpha Subunit / blood. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins / therapeutic use. T-Lymphocyte Subsets / immunology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276257.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2 Receptor alpha Subunit; 0 / Interleukins; 0 / Recombinant Proteins; 0 / interleukin-21
  •  go-up   go-down


62. Farah-Klibi F, Ferchichi L, Bouzouita A, Sfaxi M, Chebil M, Baltagi Ben Jilani S, Zermani R: [Multilocular cystic renal cell carcinoma]. Tunis Med; 2009 Mar;87(3):222-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Analyze clinicopathological features, imaging findings and prognosis and therapeutic options of this tumor.
  • The imaging findings were a renal neoplasm with cystic and solid areas.
  • [MeSH-minor] Adult. Aged. Humans. Male

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537021.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


63. Kankaanranta L, Seppälä T, Koivunoro H, Saarilahti K, Atula T, Collan J, Salli E, Kortesniemi M, Uusi-Simola J, Mäkitie A, Seppänen M, Minn H, Kotiluoto P, Auterinen I, Savolainen S, Kouri M, Joensuu H: Boron neutron capture therapy in the treatment of locally recurred head and neck cancer. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):475-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor responses were assessed using the RECIST (Response Evaluation Criteria in Solid Tumors) criteria and adverse effects using the National Cancer Institute common toxicity grading v3.0.
  • Ten (83%) patients responded to BNCT, and 2 (17%) had tumor growth stabilization for 5.5 and 7.6 months.
  • [MeSH-major] Boron Compounds / therapeutic use. Boron Neutron Capture Therapy / methods. Fructose / analogs & derivatives. Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Edema / drug therapy. Edema / etiology. Female. Fluorine Radioisotopes / therapeutic use. Humans. Male. Middle Aged. Prospective Studies. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689034.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-boronophenylalanine-fructose; 0 / Boron Compounds; 0 / Fluorine Radioisotopes; 30237-26-4 / Fructose
  •  go-up   go-down


64. Shimanovich I, Krahl D, Rose C: Trichoadenoma of Nikolowski is a distinct neoplasm within the spectrum of follicular tumors. J Am Acad Dermatol; 2010 Feb;62(2):277-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trichoadenoma of Nikolowski is a distinct neoplasm within the spectrum of follicular tumors.
  • BACKGROUND: Trichoadenoma is a rare benign follicular tumor first described by Nikolowski 50 years ago.
  • In trichoadenoma the cystic component predominates, while desmoplastic trichoepithelioma is a mostly solid neoplasm.
  • Trichoadenoma is a distinct follicular tumor related but not identical to desmoplastic trichoepithelioma.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Head and Neck Neoplasms / pathology. Humans. Immunohistochemistry. Keratin-20 / metabolism. Male. Merkel Cells / pathology. Middle Aged. Neoplasms, Fibroepithelial / pathology. Receptors, Androgen / metabolism. Skin / chemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
  • (PMID = 20115950.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Receptors, Androgen; 0 / human epithelial antigen-125
  •  go-up   go-down


65. Paydas S, Ergin M, Erdogan S, Seydaoglu G: Cyclooxygenase-2 expression in non-Hodgkin's lymphomas. Leuk Lymphoma; 2007 Feb;48(2):389-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cox-2 has been studied in solid tumors; however, studies about the role of Cox-2 in non-Hodgkin's lymphomas (NHL) are limited.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325901.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


66. Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C: Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer; 2009 May;9(2):101-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty percent of the patients had objective tumor responses; median progression-free survival was approximately 21 weeks.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Doxorubicin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Trastuzumab. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433391.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 80168379AG / Doxorubicin; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


67. Yamaguchi H, Shimizu M, Ban S, Koyama I, Hatori T, Fujita I, Yamamoto M, Kawamura S, Kobayashi M, Ishida K, Morikawa T, Motoi F, Unno M, Kanno A, Satoh K, Shimosegawa T, Orikasa H, Watanabe T, Nishimura K, Ebihara Y, Koike N, Furukawa T: Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol; 2009 Aug;33(8):1164-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor specimens were obtained from 5 men and 5 women with a mean age of 58 years.
  • ITPNs were solid and nodular tumors obstructing dilated pancreatic ducts and did not contain any visible mucin.
  • The tumor cells formed tubulopapillae and contained little cytoplasmic mucin.
  • All the features of ITPN were distinct from those of other known intraductal pancreatic neoplasms, including pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and the intraductal variant of acinar cell carcinoma.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. DNA Mutational Analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged


68. Dummer R, Rochlitz C, Velu T, Acres B, Limacher JM, Bleuzen P, Lacoste G, Slos P, Romero P, Urosevic M: Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther; 2008 May;16(5):985-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma.
  • We have conducted a phase I/II, multicenter, open-label, dose-escalating study to evaluate the safety, efficacy, and biological effects of repeated intratumoral injections of adenovirus-IL-2 (TG1024) in patients with advanced solid tumors and melanoma.
  • Thirty five patients (twenty-five with metastatic melanoma and ten with other solid tumors) were treated in eight successive cohorts at dose levels ranging from 3 x 10(8) to 3 x 10(11) viral particles (vp).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18388930.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine
  •  go-up   go-down


69. Busca A, Novarino A, de Fabritiis P, Picardi A, Zeuli M, Locatelli F, Bertetto O, Falda M: Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors. Hematology; 2006 Jun;11(3):171-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors.
  • BACKGROUND: The aim of the study was to evaluate the feasibility and efficacy of a non-myeloablative regimen to achieve complete donor chimerism after stem cell transplantation (SCT) in patients with metastatic solid tumors.
  • Regression of tumor metastases has been observed in 1 patient with RCC.
  • CONCLUSIONS: Our preliminary results suggest that non-myeloablative SCT for metastatic solid tumors is feasible, although may lead to durable responses in a minority of patients.
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Feasibility Studies. Female. Graft Survival. Graft vs Host Disease / epidemiology. Graft vs Host Disease / etiology. Graft vs Host Disease / prevention & control. Graft vs Tumor Effect. Humans. Immunosuppressive Agents / therapeutic use. Kidney Neoplasms / surgery. Male. Middle Aged. Neoplasm Metastasis. Postoperative Complications. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery. Sarcoma / secondary. Sarcoma / surgery. Survival Analysis. Transplantation, Homologous / adverse effects. Transplantation, Homologous / statistics & numerical data

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325957.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


70. Parada D, Godoy A, Liuzzi F, Pelia KB, Romero A, Parada AM: Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney. An infrequent finding. Arch Esp Urol; 2007 Apr;60(3):321-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney. An infrequent finding.
  • OBJECTIVE: Ewing's sarcoma/Primitive neuroectodermal tumor (ES/PNET) is an extraordinarily rare primary tumor in the kidney.
  • Gross pathologic examination showed pink-tan, lobulated solid tumor, localized at the superior pole.
  • RESULTS: Histologically, the tumor was solid with necrosis.
  • Adequate diagnosis is important because this neoplasm has an aggressive behaviour.
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601313.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


71. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS: Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol; 2009 Jul 20;27(21):3557-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
  • This first-in-human study evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of AMG 386 in adults with advanced solid tumors.
  • One occurrence of dose-limiting toxicity was seen at 30 mg/kg: respiratory arrest, which likely was caused by tumor burden that was possibly related to AMG 386.
  • One patient with refractory ovarian cancer achieved a confirmed partial response (ie, 32.5% reduction by Response Evaluation Criteria in Solid Tumors) and withdrew from the study with a partial response after 156 weeks of treatment; four patients experienced stable disease for at least 16 weeks.
  • AMG 386 also appeared to impact tumor vascularity and showed antitumor activity in this patient population.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / pharmacokinetics. Bevacizumab. Dose-Response Relationship, Drug. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Fatigue.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19546406.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Angiopoietins; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


72. Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T: Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts aggressive clinical course. Mod Pathol; 2006 Feb;19(2):208-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MMP-2 is associated with aggressive behavior of several solid cancers.
  • In this study, the clinical significance of tumor tissue and circulating immunoreactive proteins for MMP-2 and TIMP-2 was assessed in HNSCC.
  • Expression of MMP-2 and TIMP-2 was examined in paraffin-embedded tumor sections by immunohistochemical methods using specific antibodies.
  • Immunohistochemical overexpression of MMP-2 in tumor was found to be prognostic for shortened survival in HNSCC, the 5-year cumulative relapse-free survival being 42% in patients with high positivity for MMP-2 in tumor vs 61% in cases with a negative or only weakly MMP-2-positive tumor (P=0.045).
  • Similarly, the 5-year cause-specific survival was significantly poorer in patients with extensive positive immunostaining for tumor TIMP-2 than in those with a TIMP-2-negative tumor (40 vs 64%, P=0.038).
  • Patients with a TIMP-2-positive tumor also had an unfavorable 5-year relapse-free survival rate (43 vs 60%, respectively, P=0.071).
  • The results of this study provide evidence that MMP-2 and TIMP-2 immunoreactive protein in tumor tissue of HNSCC patients, but not when assayed from preoperative serum samples, are prognostic in estimation of the aggressive clinical course of HNSCC.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424893.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


73. Radhika S, Bakshi A, Rajwanshi A, Nijhawan R, Das A, Kakkar N, Joshi K, Marwaha RK, Rao KL: Cytopathology of uncommon malignant renal neoplasms in the pediatric age group. Diagn Cytopathol; 2005 May;32(5):281-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant renal neoplasms are common solid tumors in pediatric oncology practice.
  • These include the common Wilms' tumor/nephroblastoma and the uncommon neoplasms such as clear-cell sarcoma of the kidney (CCSK), rhabdoid tumor, renal-cell carcinoma, and others.
  • Aspirates from Wilms' tumor, which are mesenchyme predominant, show clusters of spindle cells associated with the matrix material.
  • Renal-cell carcinoma of childhood shows similar cytological features as its adult counterpart.
  • Rhabdoid tumor of the kidney is characterized by a monomorphic population of cells with abundant cytoplasm, eccentric nuclei with prominent nucleoli.
  • Intrarenal yolk sac tumor is a rare neoplasm and shows severely pleomorphic cells on aspiration.
  • Further, non-Wilms' renal malignant neoplasms must be distinguished from the common Wilms' tumor so that appropriate chemotherapy protocols may be instituted in cases where the tumor is in an advanced stage of malignancy.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma, Renal Cell / pathology. Endodermal Sinus Tumor / pathology. Kidney Neoplasms / pathology. Rhabdoid Tumor / pathology. Sarcoma, Clear Cell / pathology
  • [MeSH-minor] Adolescent. Cell Nucleus / pathology. Child. Child, Preschool. Diagnosis, Differential. Humans. Infant. Staining and Labeling. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15830360.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Schlenker B, Tilki D, Seitz M, Bader MJ, Reich O, Schneede P, Hungerhuber E, Stief CG, Gratzke C: Organ-preserving neodymium-yttrium-aluminium-garnet laser therapy for penile carcinoma: a long-term follow-up. BJU Int; 2010 Sep;106(6):786-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Neoplasm Recurrence, Local. Penile Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Humans. Male. Middle Aged. Neodymium. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20089106.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 2I87U3734A / Neodymium
  •  go-up   go-down


75. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C: Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer; 2005 Oct 15;104(8):1575-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. Age Distribution. Anthracyclines / administration & dosage. Bridged Compounds / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Incidence. Neoplasm Staging. Premenopause. Prognosis. Retrospective Studies. Tamoxifen / administration & dosage. Taxoids / administration & dosage. Time Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16134178.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Bridged Compounds; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 1605-68-1 / taxane
  •  go-up   go-down


76. Will U, Mueller A, Topalidis T, Meyer F: Value of endoscopic ultrasonography-guided fine needle aspiration (FNA) in the diagnosis of neoplastic tumor(-like) pancreatic lesions in daily clinical practice. Ultraschall Med; 2010 Apr;31(2):169-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of endoscopic ultrasonography-guided fine needle aspiration (FNA) in the diagnosis of neoplastic tumor(-like) pancreatic lesions in daily clinical practice.
  • PURPOSE: To investigate the value of EUS-guided FNA in the diagnosis of solid and cystic pancreatic tumor(-like) lesions as well as metastatic tumor growth within peripancreatic lymph nodes and its impact on therapeutic decision-making.
  • For EUS-based T-staging in 26 patients with malignant tumor lesions undergoing surgical intervention, there was a sensitivity of 73.3 % (specificity, 85.9 %; PPV, 69.2 %; NPV, 84.4 %), while the parameters for N-staging (n = 25) were: sensitivity, 61.5 %; specificity, 75 %; NPV, 64.3 %; PPV, 72.7 %.
  • While the sensitivity of EUS-guided FNA in the group of patients who underwent surgical intervention (n = 55) was 81.4 % (specificity, 75 %; PPV, 92.1 %; NPV, 52.9 %), the parameters were as follows in the subgroup of individuals with chronic pancreatitis (n = 30): sensitivity in detecting a malignant pancreatic tumor lesion, 50 %; specificity, 91.7 %; PPV, 60 %; NPV, 88 %.
  • Based on preoperative characteristics such as suspected diagnosis, TNM stage and tumor entity, a surgical intervention could be avoided in 29 / 153 patients (19 %).
  • CONCLUSION: EUS-guided FNA allows more precise diagnosis clarification (malignant tumor growth and tumor entity) in solid and cystic pancreatic tumor(-like) lesions, which may assist in early and sufficient therapeutic decision-making.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis / pathology. Lymphatic Metastasis / ultrasonography. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Pancreas / pathology. Pancreas / ultrasonography. Sensitivity and Specificity. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 19899026.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


77. Liu BA, Li ZM, Su ZS, She XL: Pathological differential diagnosis of solid-pseudopapillary neoplasm and endocrine tumors of the pancreas. World J Gastroenterol; 2010 Feb 28;16(8):1025-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological differential diagnosis of solid-pseudopapillary neoplasm and endocrine tumors of the pancreas.
  • AIM: To investigate differential points of solid-pseudopapillary neoplasm (SPN) of the pancreas and pancreatic endocrine tumor (PET).
  • The mean diameter of the tumors was 11.0 cm, 9/10 cases were cystic or a mixture of solid and cystic structures, and there was hemorrhage and necrosis on the cut surface in 8/10 (80%) cases.
  • The mean size of the tumors was 2.9 cm, most of the tumors were solid, only 3/14 (21%) were a mixture of solid and cystic structures, and macroscopic hemorrhage and necrosis were much less common (3/14, 21%).
  • Histologically, tumor cells were arranged in trabecular, acinar or solid patterns and demonstrated no pseudopapillary structure and discohesive appearance in all 14 (100%) cases.
  • [MeSH-minor] Adolescent. Adult. Base Sequence. Cadherins / genetics. Cadherins / metabolism. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Mutation. Pancreas / anatomy & histology. Pancreas / metabolism. Pancreas / pathology. Retrospective Studies. Young Adult. beta Catenin / genetics. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Jun;115 Suppl:S28-45 [11993688.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1361-9 [11943721.001]
  • [Cites] Lancet Oncol. 2003 Apr;4(4):255-6 [12681270.001]
  • [Cites] World J Gastroenterol. 2004 Jun 15;10(12):1806-9 [15188511.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • [Cites] World J Gastroenterol. 2006 May 28;12(20):3180-5 [16718837.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Nov;98(11):809-16 [17198473.001]
  • [Cites] J Surg Oncol. 2007 Mar 15;95(4):304-10 [17326131.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):251-8 [17959228.001]
  • [Cites] J Clin Pathol. 2008 Nov;61(11):1153-9 [18708424.001]
  • [Cites] Am J Surg Pathol. 2009 May;33(5):768-74 [19194274.001]
  • [Cites] Virchows Arch. 2000 May;436(5):473-80 [10881741.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1361-71 [11023097.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8401-4 [11731417.001]
  • [Cites] Am Surg. 2001 Dec;67(12):1195-9 [11768829.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):35-40 [11833495.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):818-20 [12023593.001]
  • (PMID = 20180245.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC2828590
  •  go-up   go-down


78. Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC, Libucha M, Byrley E, Balis FM, Widemann BC: Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist; 2008 Jun;13(6):679-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Pre-enrollment characteristics and study outcomes were retrospectively analyzed for children with refractory solid tumors treated in one of 16 phase I trials with similar eligibility criteria at the National Cancer Institute between 1992 and 2005.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials, Phase I as Topic. Neoplasm Recurrence, Local / therapy. Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Humans. Infant. Male. Patient Participation. Prognosis. Radiotherapy Dosage. Retrospective Studies. Stem Cell Transplantation. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586923.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


79. Black CC, Addante RR, Mohila CA: Intraosseous ameloblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Nov;110(5):585-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There are 3 subtypes: the conventional or solid-multicystic variant, the unicystic variant, and the desmoplastic variant.
  • Treatment planning for a given tumor includes consideration of location, primary versus recurrent, size, presence of cortical perforation, and age and health of the patient.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Ameloblasts / pathology. Child. Dental Enamel / pathology. Epithelium / pathology. Humans. Mesoderm / pathology. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Patient Care Planning. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • [CommentIn] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 May;111(5):536; author reply 536-8 [21306924.001]
  • (PMID = 20580278.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. da Cruz Perez DE, de Abreu Alves F, Nobuko Nishimoto I, de Almeida OP, Kowalski LP: Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncol; 2006 Feb;42(2):139-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Univariate survival analysis revealed that age older than 45 years (p = 0.04), period of complaints inferior to 18 months (p = 0.007), presence of paresthesia (p = 0.04), T stage (p = 0.01), N stage (p = 0.04), M stage (p < 0.001), clinical stage (p = 0.003), solid histological type ( p< 0.001), presence of residual tumor (p < 0.001) and expression of p53 (p = 0.08) correlated with a poor prognosis.
  • In the multivariate survival analyses, clinical stage, solid histological subtype and increased expression of p53 were independent significant prognostic factors.
  • According to our findings, clinical stage, solid growth pattern and expression of p53 were the most important prognostic factors in patients with ACC.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / therapy. Treatment Outcome. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249115.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


81. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Rentsch M, Muacevic A: Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. Ann Surg Oncol; 2010 Nov;17(11):2877-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we present the therapeutic efficacy of a robotic radiosurgery for local control of liver metastases from solid tumors.
  • METHODS: Patients with tumorous lesions to the liver, not qualifying for surgery, were treated with single-session radiosurgery (24 Gy) that used robotic image-guided real-time tumor tracking.
  • For inclusion into the radiosurgery treatment protocol, tumor volumes had to be <90 ml.
  • Median tumor volume was 18 ml (range, 2.2-90 ml).
  • CONCLUSIONS: Robotic radiosurgery with image-guided real-time tumor tracking of liver neoplasm is a new and promising approach for patients with disease that is not eligible for surgical resection and might enhance the possibilities of multidisciplinary oncological treatment concepts.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20574773.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Müller HL, Gebhardt U, Pohl F, Flentje M, Emser A, Warmuth-Metz M, Kolb R, Calaminus G, Sörensen N: Relapse pattern after complete resection and early progression after incomplete resection of childhood craniopharyngioma. Klin Padiatr; 2006 Nov-Dec;218(6):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A high rate of early events (1y-EFS: 0.78 +/- 0.10; 2y-EFS: 0.57 +/- 0.15) was also found for patients after XRT (3 cystic progressions, 3 progressions of solid tumour; in 24 patients after XRT).
  • [MeSH-major] Craniopharyngioma / surgery. Neoplasm Recurrence, Local. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Child. Child, Preschool. Disease Progression. Follow-Up Studies. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Multicenter Studies as Topic. Neoplasm, Residual. Prospective Studies. Radiotherapy Dosage. Reoperation. Surveys and Questionnaires. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080333.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


83. Antedomenico E, Wascher RA: A case of mistaken identity: giant cystic pheochromocytoma. Curr Surg; 2005 Mar-Apr;62(2):193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on these findings and the patient's history, a cystic neoplasm of the pancreas was suspected, and she was subsequently taken to the operating room for exploration.
  • Cystic PCCs may not present with the classic prodromal symptoms associated with solid PCCs.
  • This case represents the complex and unsuspected presentation of an extremely rare functional cystic neoplasm.
  • [MeSH-minor] Adrenal Gland Neoplasms. Adult. Antihypertensive Agents / administration & dosage. Female. Humans. Hypertension / drug therapy. Hypertension / etiology. Infusions, Intravenous. Nitroprusside / administration & dosage. Surgical Procedures, Operative. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796940.001).
  • [ISSN] 0149-7944
  • [Journal-full-title] Current surgery
  • [ISO-abbreviation] Curr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 169D1260KM / Nitroprusside
  •  go-up   go-down


84. Landa J, Allen P, D'Angelica M, Schwartz LH: Recurrence patterns of intraductal papillary mucinous neoplasms of the pancreas on enhanced computed tomography. J Comput Assist Tomogr; 2009 Nov-Dec;33(6):838-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Computed tomography findings suspicious for tumor recurrence include enlarging mass (either solid, cystic or both), progressive ductal dilatation, or extrapancreatic disease.
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Carcinoma, Papillary / radiography. Neoplasm Recurrence, Local / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Female. Humans. Iohexol. Male. Middle Aged. Radiographic Image Interpretation, Computer-Assisted. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19940647.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


85. Schatton T, Frank MH: Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res; 2008 Feb;21(1):39-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer stem cells (CSC) have been identified in hematological malignancies and several solid cancers.
  • Similar to physiological stem cells, CSC are capable of self-renewal and differentiation and have the potential for indefinite proliferation, a function through which they may cause tumor growth.
  • Although conventional anti-cancer treatments might eradicate most malignant cells in a tumor, they are potentially ineffective against chemoresistant CSC, which may ultimately be responsible for recurrence and progression.
  • Detection of tumor heterogeneity, undifferentiated molecular signatures, and increased tumorigenicity of melanoma subsets with embryonic-like differentiation plasticity strongly suggest the presence and involvement of malignant melanoma stem cells (MMSC) in the initiation and propagation of this malignancy.
  • We propose that a subset of MMSC may be responsible for melanoma therapy-resistance, tumor invasiveness, and neoplastic progression and that targeted abrogation of a MMSC compartment could therefore ultimately lead to stable remissions and perhaps cures of metastatic melanoma.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med J Aust. 1997 Aug 18;167(4):191-4 [9293264.001]
  • [Cites] Dev Biol. 1997 Dec 1;192(1):99-107 [9405100.001]
  • [Cites] Histopathology. 1997 Nov;31(5):465-8 [9416488.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2170-5 [9605762.001]
  • [Cites] Blood. 1998 Sep 15;92(6):2041-52 [9731062.001]
  • [Cites] Nature. 1998 Nov 26;396(6709):370-3 [9845073.001]
  • [Cites] Cell. 1998 Nov 25;95(5):605-14 [9845363.001]
  • [Cites] Science. 1999 Feb 5;283(5403):845-8 [9933168.001]
  • [Cites] Semin Cancer Biol. 1998 Dec;8(6):447-53 [10191179.001]
  • [Cites] Development. 1999 May;126(10):2285-98 [10207152.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):739-52 [10487832.001]
  • [Cites] J Embryol Exp Morphol. 1958 Dec;6(4):530-45 [13611133.001]
  • [Cites] Nature. 1963 Jul 6;199:79-80 [14047954.001]
  • [Cites] Curr Opin Cell Biol. 2004 Dec;16(6):700-7 [15530784.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Science. 2004 Nov 26;306(5701):1568-71 [15567866.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):28-44 [15617989.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):769-74 [10702391.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(3):359-75 [10721490.001]
  • [Cites] J Biol Chem. 2000 May 12;275(19):14013-6 [10747853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7882-7 [10884419.001]
  • [Cites] J Biol Chem. 2003 Nov 21;278(47):47156-65 [12960149.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jan;5(1):45-54 [14708009.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Lancet. 2004 May 1;363(9419):1411-2 [15121399.001]
  • [Cites] Lancet. 2004 May 1;363(9419):1439-41 [15121408.001]
  • [Cites] Science. 2004 May 28;304(5675):1338-40 [15060285.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 16;320(1):226-32 [15207725.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1444-53 [15240741.001]
  • [Cites] Pigment Cell Res. 2004 Aug;17(4):318-25 [15250933.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5270-82 [15289333.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5385-9 [15289346.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1473-7 [15467037.001]
  • [Cites] Dev Biol. 1973 Sep;34(1):39-46 [4595498.001]
  • [Cites] Biochim Biophys Acta. 1976 Oct 12;458(3):283-321 [1067873.001]
  • [Cites] Science. 1977 Jul 29;197(4302):461-3 [560061.001]
  • [Cites] Science. 1977 Aug 26;197(4306):893-5 [887927.001]
  • [Cites] Cancer Treat Rev. 1978 Dec;5(4):195-8 [367596.001]
  • [Cites] Science. 1982 Sep 10;217(4564):998-1003 [7112116.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5):413-26 [12407507.001]
  • [Cites] J Biomed Sci. 2002 Nov-Dec;9(6 Pt 2):564-73 [12432222.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1593-603 [12432047.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):522-36 [12492494.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7328-34 [12499276.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Recent Results Cancer Res. 2003;161:93-110 [12528802.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2397-402 [12606728.001]
  • [Cites] Dev Biol. 2003 Mar 15;255(2):238-48 [12648487.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):370-1 [12653588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nature. 2003 Apr 24;422(6934):897-901 [12665832.001]
  • [Cites] J Am Acad Dermatol. 2003 May;48(5):663-71 [12734494.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):411-21 [12778131.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2881-90 [12782594.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3138-51 [12789290.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):559-70 [12894244.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):3166-76 [16239965.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Development. 2005 Dec;132(24):5589-99 [16314490.001]
  • [Cites] Dev Cell. 2005 Dec;9(6):855-61 [16326396.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):523-6 [16258898.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):899-904 [16327766.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):246-54 [16341148.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2223-33 [16291593.001]
  • [Cites] Dev Biol. 2006 Mar 1;291(1):144-53 [16427619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3752-7 [16505384.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2301s-2307s [16609049.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2326s-2330s [16609053.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4182-90 [16618740.001]
  • [Cites] Nature. 2006 Apr 27;440(7088):1199-203 [16565704.001]
  • [Cites] J Cell Biol. 2006 May 8;173(3):333-9 [16651378.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1372-7 [16470173.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1214-6 [16702970.001]
  • [Cites] Nature. 2006 May 25;441(7092):475-82 [16598206.001]
  • [Cites] Nature. 2006 May 25;441(7092):437-43 [16724055.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):536-40 [10952317.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1278-81 [11062542.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):678-83 [11333289.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Cytometry. 2001 Aug 15;46(4):222-32 [11514955.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1028-34 [11533706.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] Nature. 2002 Apr 25;416(6883):854-60 [11976685.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):155-66 [11994736.001]
  • [Cites] Cell. 2002 May 31;109(5):625-37 [12062105.001]
  • [Cites] Recent Results Cancer Res. 2002;160:332-42 [12079231.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):279-88 [12086864.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):41-9 [12077603.001]
  • [Cites] Nat Med. 2002 Aug;8(8):793-800 [12091876.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):823 [12192390.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1269-81 [16814714.001]
  • [Cites] Nat Med. 2006 Aug;12(8):925-32 [16892036.001]
  • [Cites] Genes Dev. 2006 Aug 15;20(16):2149-82 [16912270.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] J Cell Biol. 2006 Oct 9;175(1):99-110 [17015616.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):8914-27 [17000761.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Oncogene. 2006 Dec 14;25(59):7663-72 [16847453.001]
  • [Cites] Genes Dev. 2006 Dec 15;20(24):3426-39 [17182868.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] N Engl J Med. 2007 Jan 18;356(3):294-7 [17229957.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):834-42 [17314969.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):935-46 [17320377.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):246-55 [17384580.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] Oncologist. 2003;8(5):459-65 [14530499.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):836-41 [14574412.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):841-6 [14574413.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6751-7 [14583470.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):962-7 [14574365.001]
  • [Cites] Hum Pathol. 1984 Dec;15(12):1147-65 [6500548.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5670-6 [4053039.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5167-71 [3756870.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(19):7307-10 [3463969.001]
  • [Cites] Lab Invest. 1987 May;56(5):461-74 [3553733.001]
  • [Cites] J Cutan Pathol. 1987 Aug;14(4):255 [3624588.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1329-37 [2364430.001]
  • [Cites] Cancer Surv. 1990;9(4):645-71 [2101727.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1237-40 [1878591.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1707-10 [1553558.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Development. 1995 May;121(5):1547-57 [7540532.001]
  • [Cites] Nat Genet. 1995 Nov;11(3):328-30 [7581459.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Nature. 1996 Mar 14;380(6570):171-5 [8600394.001]
  • [Cites] J Invest Dermatol. 1996 May;106(5):967-71 [8618059.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1797-806 [8666936.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1790-2 [9065403.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Pigment Cell Res. 1996 Dec;9(6):304-10 [9125754.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):45-60 [15617990.001]
  • [Cites] FASEB J. 2005 Jan;19(1):147-9 [15498892.001]
  • [Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]
  • [Cites] Science. 2005 Feb 4;307(5710):720-4 [15618488.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] Nature. 2005 Feb 24;433(7028):884-7 [15729346.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1835-41 [15756007.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5530-4 [15802470.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Pigment Cell Res. 2005 Jun;18(3):150-9 [15892711.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4320-33 [15899824.001]
  • [Cites] J Exp Med. 2005 Jun 6;201(11):1781-91 [15928197.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] Dev Dyn. 2005 Aug;233(4):1560-70 [15968639.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Front Biosci. 2006;11:733-42 [16146765.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1047-54 [16142232.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Nature. 2006 Jun 29;441(7097):1068-74 [16810241.001]
  • [Cites] Nature. 2006 Jun 29;441(7097):1075-9 [16810242.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] Stem Cells. 2007 Apr;25(4):1003-12 [17185612.001]
  • [Cites] Oncogene. 2007 Jun 14;26(28):4158-70 [17173062.001]
  • [Cites] J Surg Res. 2007 Jul;141(1):72-7 [17574040.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):862-72 [17171636.001]
  • [Cites] J Cell Biochem. 2007 Jul 1;101(4):979-86 [17390343.001]
  • [Cites] Pigment Cell Res. 2007 Aug;20(4):263-70 [17630959.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2854-60 [17593331.001]
  • [Cites] Carcinogenesis. 2007 Oct;28(10):2172-83 [17449903.001]
  • [Cites] J Invest Dermatol. 2008 Feb;128(2):408-20 [17657242.001]
  • (PMID = 18353142.001).
  • [ISSN] 1755-1471
  • [Journal-full-title] Pigment cell & melanoma research
  • [ISO-abbreviation] Pigment Cell Melanoma Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113796-05; United States / NCI NIH HHS / CA / P50 CA093683-07; United States / NCI NIH HHS / CA / R01 CA113796; United States / NCI NIH HHS / CA / R01 CA113796-04; United States / NCI NIH HHS / CA / R01 CA113796-01A1; United States / NCI NIH HHS / CA / CA113796-05; United States / NCI NIH HHS / CA / P50 CA093683; United States / NCI NIH HHS / CA / CA113796-02; United States / NCI NIH HHS / CA / CA113796-01A1; United States / NCI NIH HHS / CA / CA113796-04; United States / NCI NIH HHS / CA / P50 CA093683-08; United States / NCI NIH HHS / CA / CA113796-03; United States / NCI NIH HHS / CA / CA093683-06A2; United States / NCI NIH HHS / CA / R01 CA113796-02; United States / NCI NIH HHS / CA / R01 CA113796-03; United States / NCI NIH HHS / CA / P50 CA093683-06A2; United States / NCI NIH HHS / CA / 1R01CA113796-01A1; United States / NCI NIH HHS / CA / 2P50CA093683-05S2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 180
  • [Other-IDs] NLM/ NIHMS209140; NLM/ PMC2885609
  •  go-up   go-down


86. Darius T, Brouwers J, Van Dijck H, Bernard P: Solid and cystic papillary neoplasm of the pancreas: a rare tumour in young women. Acta Chir Belg; 2006 Nov-Dec;106(6):726-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid and cystic papillary neoplasm of the pancreas: a rare tumour in young women.
  • In this paper, we present an asymptomatic young patient with solid and cystic papillary neoplasm of the pancreas.
  • In differential diagnosis, any cystic and/or solid pancreatic disease process should be considered.
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290708.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


87. Alaa M, Suzuki M, Yoshino M, Tian L, Suzuki H, Nagato K, Fujiwara T, Wada H, Moriya Y, Hoshino H, Motohashi S, Yoshida S, Shibuya K, Hiroshima K, Nakatani Y, Abdrabou A, Elkholy M, Mahfouz T, Yoshino I: Prostaglandin E2 receptor 2 overexpression in squamous cell carcinoma of the lung correlates with p16INK4A methylation and an unfavorable prognosis. Int J Oncol; 2009 Mar;34(3):805-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several studies have described p16INK4A and prostaglandin E2 (PGE2) co-alterations in various solid tumors, including non-small cell lung cancer (NSCLC).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Prostaglandin E, EP2 Subtype. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212685.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / PTGER2 protein, human; 0 / Receptors, Prostaglandin E; 0 / Receptors, Prostaglandin E, EP2 Subtype
  •  go-up   go-down


88. Capurso G, Crnogorac-Jurcevic T, Milione M, Panzuto F, Campanini N, Dowen SE, Di Florio A, Sette C, Bordi C, Lemoine NR, Delle Fave G: Peanut-like 1 (septin 5) gene expression in normal and neoplastic human endocrine pancreas. Neuroendocrinology; 2005;81(5):311-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of the PNUTL1 protein was also evaluated by immunohistochemistry on normal pancreas, additional 26 PETs, eight pancreatic adenocarcinomas, one mixed endocrine-exocrine pancreatic neoplasm, a specimen of solid papillary pseudomucinous tumor, an adult islet cell hyperplasia and a case of neonatal nesidioblastosis.
  • In addition, a tissue array (LandMark High Density Cancer Tissue MicroArray) comprising 280 various tumor and matched normal specimens was utilized.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Northern / methods. Female. Humans. Immunohistochemistry / methods. Infant. Juniperus / metabolism. Male. Middle Aged. Protein Array Analysis / methods. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Septins

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16179808.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / RNA, Messenger; EC 3.6.1.- / SEPT5 protein, human; EC 3.6.1.- / Septins
  •  go-up   go-down


89. Buti S, Lazzarelli S, Chiesa MD, Simonelli C, Re GL, Lheshi A, Simon S, Mattioli R, Caminiti C, Mazza G, Donini M, Passalacqua R, GOIRC (Italian Oncology Group for Clinical Research): Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study. J Immunother; 2010 Sep;33(7):735-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The response rate was 33% according to the Response Evaluation Criteria in Solid Tumors.
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Intention to Treat Analysis. Interferon-alpha / administration & dosage. Interleukin-2 / administration & dosage. Italy. Male. Maximum Tolerated Dose. Medical Oncology. Middle Aged. Neoplasm Metastasis. Survival Analysis

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664353.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Interferon-alpha; 0 / Interleukin-2; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


90. Bianco Ade M, Madeira LV, Rosemberg S, Shibata MK: Cortical seeding of a craniopharyngioma after craniotomy: Case report. Surg Neurol; 2006 Oct;66(4):437-40; discussion 440
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A left frontotemporal craniotomy was done with subtotal resection of the tumor because it was strongly adhered to the optic chiasm.
  • Magnetic resonance imaging revealed a contrast-enhancing tumor with cystic and solid components on the left temporal lobe cortex.
  • The primary tumor bed was intact.
  • The patient was reoperated, and the temporal lobe tumor was totally removed.
  • [MeSH-major] Brain Neoplasms / secondary. Craniopharyngioma / secondary. Neoplasm Seeding. Pituitary Neoplasms / pathology. Temporal Lobe / pathology
  • [MeSH-minor] Adult. Craniotomy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Neurosurgical Procedures / methods. Neurosurgical Procedures / standards. Optic Chiasm / pathology. Optic Chiasm / physiopathology. Seizures / etiology. Seizures / physiopathology. Treatment Outcome. Vision, Low / etiology. Vision, Low / physiopathology


91. Szczublewski P, Szpurek D, Moszyński R, Szubert S, Sajdak S: [Assessment of ultrasonography markers and CA125 usefulness in the diagnosis of ovarian cysts]. Ginekol Pol; 2008 Dec;79(12):856-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: 187 premenopausal women with ovarian tumor (between the ages of 13 and 52) were enrolled in the study.
  • Each patient underwent transvaginal ultrasonography and the morphology of the tumor was assessed on the basis of morphological index.
  • RESULTS: Functional ovarian cysts in ultrasonography included: unilocular with smooth internal wall, anechoic, without solid elements and with a thin wall of the structure (< 3 mm).
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / blood. Female. Humans. Middle Aged. Neoplasm Staging. Poland. ROC Curve. Regression Analysis. Ultrasonography. Women's Health. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175043.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


92. Maecker B, von Bergwelt-Baildon MS, Sherr DH, Nadler LM, Schultze JL: Identification of a new HLA-A*0201-restricted cryptic epitope from CYP1B1. Int J Cancer; 2005 Jun 10;115(2):333-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytochrome P450 1B1 (CYP1B1) was recently shown to be a candidate tumor antigen broadly expressed in solid and hematologic malignancies.
  • Lysis of CYP1B1-expressing, HLA-A*0201+ tumor cell lines and primary tumor cells confirmed that sufficient levels of CYP246 are presented by tumor cells for effector CTL killing.
  • These findings indicate that CYP246 is a candidate cryptic epitope for immune interventions in which tumor CYP1B1 is targeted.
  • [MeSH-minor] Algorithms. Antigen-Presenting Cells / immunology. Antigens, CD40 / immunology. Antigens, CD40 / metabolism. Antigens, Neoplasm / immunology. Antigens, Neoplasm / metabolism. B-Lymphocytes / immunology. Cytochrome P-450 CYP1B1. Cytochrome P-450 Enzyme System / immunology. Cytochrome P-450 Enzyme System / metabolism. Epitopes. HLA-A2 Antigen. Half-Life. Humans. Neoplasm Proteins / immunology. Neoplasm Proteins / metabolism. T-Lymphocytes / immunology. T-Lymphocytes, Cytotoxic / immunology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15688394.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA-66996; United States / NCI NIH HHS / CA / P01-CA-78378; United States / NIEHS NIH HHS / ES / P01-ES-11624; United States / NHLBI NIH HHS / HL / P01-HL-68705; United States / NIEHS NIH HHS / ES / R01-ES-06086
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Antigens, Neoplasm; 0 / Epitopes; 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / MAGEA3 protein, human; 0 / Neoplasm Proteins; 0 / Peptide Fragments; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; EC 1.14.14.1 / retinoic acid 4-hydroxylase
  •  go-up   go-down


93. Freier K, Flechtenmacher C, Walch A, Ohl S, Devens F, Burke B, Hassfeld S, Lichter P, Joos S, Hofele C: Copy number gains on 22q13 in adenoid cystic carcinoma of the salivary gland revealed by comparative genomic hybridization and tissue microarray analysis. Cancer Genet Cytogenet; 2005 May;159(1):89-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenoid cystic carcinoma (ACC) of the salivary gland is a neoplasm characterized by slow but inevitable local progression and terminal hematogenous metastasis.
  • The overall prevalence of copy number gains on 22q13 was 30% of the tumors in the fluorescence in situ hybridization analysis, irrespective of histologic differentiation (cribriform/tubular vs. solid) or tumor event (primary vs. recurrent).
  • We therefore assume that copy number gain of 22q13 is a novel frequent finding in ACC that may be involved in the initial pathogenesis of this neoplasm by proto-oncogene activation.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Neoplasm / genetics. Female. Gene Dosage. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860365.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


94. Saghafi S, Zare-Mahmoodabadi R, Salehinejad J, Kadeh H, Afzal-Aghaee M: Immunohistochemical analysis of p53 and PCNA expression in calcifying odontogenic cyst. J Oral Sci; 2010 Dec;52(4):609-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of its diverse histopathologic features and biological behavior, there has long been confusion with regard to its nature as a cyst or neoplasm.
  • This study evaluated the proliferative activity of 57 COC samples, including simple cyst (10 cases), cystic neoplasm (34 cases), solid neoplasm (6 cases) and combined lesion (7 cases) by p53 and PCNA immunohistochemical staining.
  • For assessment of p53 and PCNA positivity, the number of positively stained cells with brown-stained nuclei was counted in 1000 cells from each sample. p53 and PCNA expression in the solid neoplasm subtype were significantly higher when compared to cystic neoplasm and simple cyst (P < 0.05).
  • The lowest p53 and PCNA expression was found in the simple cyst subtype. p53 and PCNA expression in the basal and suprabasal layers was significantly higher in the solid subtype when compared to others, and the difference between COC groups was significant.
  • [MeSH-major] Jaw Neoplasms / metabolism. Odontogenic Cyst, Calcifying / metabolism. Proliferating Cell Nuclear Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21206164.001).
  • [ISSN] 1880-4926
  • [Journal-full-title] Journal of oral science
  • [ISO-abbreviation] J Oral Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


95. Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, Eisenfeld A, Singer JW, Oldham FB: A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol; 2009 Apr;63(5):903-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.
  • PATIENTS AND METHODS: Forty-three patients with advanced solid tumors were treated at escalating doses of PPX with a fixed dose of cisplatin at 75 mg/m(2).
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cohort Studies. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Polyglutamic Acid / administration & dosage. Polyglutamic Acid / analogs & derivatives. Prognosis. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682950.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / paclitaxel poliglumex; 25513-46-6 / Polyglutamic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


96. Mobasheri MB, Modarressi MH, Shabani M, Asgarian H, Sharifian RA, Vossough P, Shokri F: Expression of the testis-specific gene, TSGA10, in Iranian patients with acute lymphoblastic leukemia (ALL). Leuk Res; 2006 Jul;30(7):883-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Testis-specific gene antigen (TSGA10) is expressed in fetus, testis and frequently in human solid cancers and acute leukemias, making it a candidate for immunotherapy and for detection of minimal residual disease (MRD).
  • TSGA10 expression has been observed in a wide spectrum of cancers but not in hematopoietic neoplasm.
  • [MeSH-minor] Adolescent. Adult. Child. Gene Expression Profiling. Humans. Iran / epidemiology. Molecular Sequence Data. Polymorphism, Restriction Fragment Length. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406020.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AI696619/ AW057728/ AW591313/ BE047007/ BF243403
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteins; 0 / TSGA10 protein, human
  •  go-up   go-down


97. Fekrazad HM, Verschraegen CF, Royce M, Smith HO, Chyi Lee F, Rabinowitz I: A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer. Am J Clin Oncol; 2010 Aug;33(4):393-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients with advanced solid tumors were treated with gemcitabine 800 mg/m and irinotecan 80 mg/m on day 1, followed by flavopiridol, starting dose of 30 mg/m on day 2 with increment of 15 mg/m per dose level, repeated on days 8 and 9 for the first 6 patients (3-week cycle), and then repeated on days 15 and 16 for the remainder patients (4-week cycle).
  • RESULTS: Fourteen women and 7 men with advanced solid tumors were enrolled.
  • [MeSH-major] Antineoplastic Agents / toxicity. Flavonoids / toxicity. Neoplasm Metastasis / drug therapy. Piperidines / toxicity
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / toxicity. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Life Expectancy. Male. Middle Aged. Patient Selection

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884803.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Flavonoids; 0 / Piperidines; 0W860991D6 / Deoxycytidine; 45AD6X575G / alvocidib; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


98. Brignardello E, Corrias A, Isolato G, Palestini N, Cordero di Montezemolo L, Fagioli F, Boccuzzi G: Ultrasound screening for thyroid carcinoma in childhood cancer survivors: a case series. J Clin Endocrinol Metab; 2008 Dec;93(12):4840-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solid thyroid nodules were found in 35 patients.
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Biopsy, Fine-Needle. Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / pathology. Carcinoma, Papillary, Follicular / ultrasonography. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Long-Term Care. Male. Neoplasm Metastasis / pathology. Thyroid Function Tests. Thyroid Nodule / ultrasonography. Thyroidectomy. Young Adult


99. Wang DB, Wang QB, Chai WM, Chen KM, Deng XX: Imaging features of solid pseudopapillary tumor of the pancreas on multi-detector row computed tomography. World J Gastroenterol; 2009 Feb 21;15(7):829-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging features of solid pseudopapillary tumor of the pancreas on multi-detector row computed tomography.
  • AIM: To retrospectively analyze the imaging features of solid-pseudopapillary tumors (SPTs) of the pancreas on multi-detector row computed tomography (MDCT) and define the imaging findings suggestive of malignant potential.
  • When the size of the tumor was greater than 6 cm (including 6 cm), the possibilities of vascular (8 vs 1) and capsular invasion (9 vs 0) increased significantly (P < 0.05).
  • These imaging findings are predictive of the malignant potential associated with the aggressive behavior of the tumor, even in the pathologically benign cases.
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Jaundice / etiology. Male. Middle Aged. Neoplasm Invasiveness. Pain / etiology. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Radiol. 2005 Aug;35(8):819-22 [15864574.001]
  • [Cites] Surgery. 2005 Jun;137(6):591-6 [15933625.001]
  • [Cites] Pancreas. 2006 Apr;32(3):276-80 [16628083.001]
  • [Cites] World J Gastroenterol. 2007 Mar 28;13(12):1811-5 [17465471.001]
  • [Cites] JOP. 2008;9(2):150-9 [18326922.001]
  • [Cites] Semin Diagn Pathol. 2000 Feb;17(1):66-80 [10721808.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):35-40 [11833495.001]
  • [Cites] J Pediatr Surg. 2002 Sep;37(9):1370-3 [12194139.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):419-25 [14736675.001]
  • [Cites] Am J Surg Pathol. 1979 Feb;3(1):69-75 [534384.001]
  • [Cites] Radiology. 1984 Jan;150(1):39-40 [6689785.001]
  • [Cites] Cancer. 1984 Oct 1;54(7):1469-74 [6467170.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;416(6):535-8 [2110701.001]
  • [Cites] Radiology. 1996 Jun;199(3):707-11 [8637992.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):512-9 [15767807.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):965-72 [15922212.001]
  • [Cites] JOP. 2006;7(1):131-6 [16407635.001]
  • (PMID = 19230043.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2653382
  •  go-up   go-down


100. Kim JY, Lim SJ, Park K, Lee CM, Kim J: Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays. Gynecol Oncol; 2005 May;97(2):337-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
  • OBJECTIVES: Cyclooxygenase-2 (COX-2) and c-erbB-2 are involved in the pathogenesis of solid organ tumors.
  • This study evaluated the significance and relationship of COX-2 and c-erbB-2 protein expression in untreated uterine cervical neoplasm.
  • METHODS: This study included 332 patients with uterine cervical neoplasm.
  • We constructed tissue microarray blocks that included two cores from each donor tumor and immunostained them with primary anti-cyclooxygenase-2 and anti-c-erbB-2 monoclonal antibodies.
  • RESULTS: Three hundred and eighteen tumor samples (95.8%) could be interpreted after immunohistochemical staining.
  • COX-2 protein expression was noted in 140 cases of uterine cervical neoplasm (44.0%): In 26.7% of the cervical intraepithelial neoplasia III (16/60 cases), 37.9% of the microinvasive squamous cell carcinoma (39/103 cases), 51.6% of the invasive squamous cell carcinoma (64/124 cases), and 76.2% of the adenocarcinomas (16/21 cases) (P < 0.005).
  • By contrast, except for one case of adenoid cystic carcinoma, none of the uterine cervical neoplasm expressed c-erbB-2 protein.
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Cyclooxygenase 2. Female. Humans. Immunohistochemistry. Membrane Proteins. Microarray Analysis. Middle Aged






Advertisement